HealthLynked (HLYK) 10-Q 15 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 13, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	HealthLynked Corp
Entity Central Index Key	0001680139
Trading Symbol	HLYK
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		98,163,226

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current Assets
Cash	$ 514,309	$ 135,778
Accounts receivable, net of allowance for doubtful accounts of $13,972 and $13,972 as of March 31, 2019 and December 31, 2018, respectively	106,905	114,884
Prepaid expenses	18,639	28,542
Deferred offering costs	57,609	96,022
Total Current Assets	697,462	375,226
Property, plant and equipment, net of accumulated depreciation of $683,494 and $752,173 as of March 31, 2019 and December 31, 2018, respectively	23,837	42,597
ROU lease assets, long term portion and deposits	364,987	9,540
Total Assets	1,086,286	427,363
Current Liabilities
Accounts payable and accrued expenses	447,096	394,333
Capital lease, current portion		19,877
Lease liability, current portion	266,130
Due to related party, current portion	446,276	429,717
Notes payable to related party, current portion	678,329	672,471
Convertible notes payable, net of original issue discount and debt discount of $363,089 and $386,473 as of March 31, 2019 and December 31, 2018, respectively	1,057,315	1,042,314
Derivative financial instruments	580,855	800,440
Total Current Liabilities	3,476,001	3,359,152
Long-Term Liabilities
Capital leases, long-term portion		3,058
Lease liability, long term portion	90,387
Total Liabilities	3,566,388	3,362,210
Shareholders' Deficit
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 93,577,019 and 85,178,902 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	9,358	8,518
Common stock issuable, $0.0001 par value; 205,301 and 114,080 shares as of March 31, 2019 and December 31, 2018, respectively	46,097	26,137
Additional paid-in capital	9,026,215	7,531,553
Accumulated deficit	(11,561,772)	(10,501,055)
Total Shareholders' Deficit	(2,480,102)	(2,934,847)
Total Liabilities and Shareholders' Deficit	$ 1,086,286	$ 427,363

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accounts receivable, net of allowance for doubtful accounts	$ 13,972	$ 13,972
Property, plant and equipment, net of accumulated depreciation	683,494	752,173
Convertible notes payable, net of original issue discount and debt discount	$ 363,089	$ 386,473
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	93,577,019	85,178,902
Common stock, shares outstanding	93,577,019	85,178,902
Common stock issuable, par value	$ 0.0001	$ 0.0001
Common stock issuable, shares	205,301	114,080

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue
Patient service revenue, net	$ 464,990	$ 645,639
Operating Expenses
Salaries and benefits	529,225	560,856
General and administrative	757,356	574,828
Depreciation and amortization	1,655	6,029
Total Operating Expenses	1,288,236	1,141,713
Loss from operations	(823,246)	(496,074)
Other Income (Expenses)
Loss on extinguishment of debt	(139,798)	(325,223)
Change in fair value of debt	(29,697)	(57,946)
Financing cost	(33,903)	(192,062)
Amortization of original issue and debt discounts on notes payable and convertible notes	(179,384)	(154,835)
Change in fair value of derivative financial instrument	191,633	(14,621)
Interest expense	(46,322)	(40,347)
Total other expenses	(237,471)	(785,034)
Net loss before provision for income taxes	(1,060,717)	(1,281,108)
Provision for income taxes
Net loss	$ (1,060,717)	$ (1,281,108)
Net loss per share, basic and diluted:
Basic	$ (0.01)	$ (0.02)
Fully diluted	$ (0.01)	$ (0.02)
Weighted average number of common shares:
Basic	88,506,930	72,907,455
Fully diluted	88,506,930	72,907,455

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Shareholders' Deficit (Unaudited) - USD ($)	Common Stock	Common Stock Issuable	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 7,230	$ 8,276	$ 2,638,311	$ (4,705,230)	$ (2,051,413)
Balance, shares at Dec. 31, 2017	72,302,937
Sale of common stock	$ 63	236	133,312		133,611
Sale of common stock, shares	631,204
Fair value of warrants allocated to proceeds of common stock			117,956		117,956
Fair value of warrants issued to extend related party notes payable			337,467		337,467
Fair value of warrants issued to extend convertible notes payable			10,199		10,199
Consultant fees payable with common shares and warrants		5,287			5,287
Consultant fees payable with common shares and warrants, shares
Shares and options issued pursuant to employee equity incentive plan	$ 8	(8)	5,577		5,577
Shares and options issued pursuant to employee equity incentive plan, shares	75,000
Net loss				(1,281,108)	(1,281,108)
Balance at Mar. 31, 2018	$ 7,301	13,791	3,242,822	(5,986,338)	(2,722,424)
Balance, Shares at Mar. 31, 2018	73,009,141
Balance at Dec. 31, 2018	$ 8,518	26,137	7,531,553	(10,501,055)	(2,934,847)
Balance, shares at Dec. 31, 2018	85,178,902
Sale of common stock	$ 326		693,832		694,158
Sale of common stock, shares	3,261,978
Fair value of warrants allocated to proceeds of common stock			139,068		139,068
Shares issued with convertible notes payable	$ 3		4,673		4,676
Shares issued with convertible notes payable, shares	28,000
Fair value of warrants issued for professional services			54,257		54,257
Conversion of convertible notes payable to common stock	$ 251		534,980		535,231
Conversion of convertible notes payable to common stock, shares	2,512,821
Consultant fees payable with common shares and warrants	$ 27	19,960	6,850		26,837
Consultant fees payable with common shares and warrants, shares	270,000
Shares and options issued pursuant to employee equity incentive plan	$ 12		61,223		61,235
Shares and options issued pursuant to employee equity incentive plan, shares	113,750
Exercise of stock warrants	$ 210		(210)
Exercise of stock warrants, shares	2,098,427
Exercise of stock options	$ 11		(11)
Exercise of stock options, shares	113,141
Net loss				(1,068,756)	(1,060,717)
Balance at Mar. 31, 2019	$ 9,358	$ 46,097	$ 9,026,215	$ (11,569,811)	$ (2,480,102)
Balance, Shares at Mar. 31, 2019	93,577,019

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows from Operating Activities
Net loss	$ (1,060,717)	$ (1,281,108)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,655	6,029
Stock based compensation, including amortization of prepaid fees	180,741	23,666
Amortization of original issue discount and debt discount on convertible notes	179,384	154,835
Financing cost	33,903	192,062
Change in fair value of derivative financial instrument	(191,633)	14,621
Loss on extinguishment of debt	139,798	325,223
Change in fair value of debt	29,697	57,946
Changes in operating assets and liabilities:
Accounts receivable	7,979	(36,174)
Prepaid expenses and deposits	9,903	12,575
Accounts payable and accrued expenses	51,237	90,336
Lease liability	1,070
Due to related party, current portion	16,590	15,835
Net cash used in operating activities	(600,393)	(424,154)
Cash Flows from Investing Activities
Acquisition of property and equipment	(4,302)	(201)
Net cash used in investing activities	(4,302)	(201)
Cash Flows from Financing Activities
Proceeds from sale of common stock	833,226	251,568
Proceeds from issuance of convertible notes	150,000	325,000
Repayment of convertible notes		(209,682)
Proceeds from related party loans		101,450
Repayment of related party loans		(9,000)
Repayment of notes payable and bank loans		(52,619)
Payments on capital leases		(3,058)
Net cash provided by financing activities	983,226	403,659
Net increase (decrease) in cash	378,531	(20,696)
Cash, beginning of period	135,778	50,006
Cash, end of period	514,309	29,310
Supplemental disclosure of cash flow information:
Cash paid during the period for interest	830	7,117
Cash paid during the period for income tax
Schedule of non-cash investing and financing activities:
Fair value of beneficial conversion feature and original issue discount allocated to proceeds of convertible notes payable	179,227
Common stock issuable issued during period	4,483
Fair of warrants issued for professional service	14,743
Conversion of convertible note payable to common shares	535,231
Fair value of common shares issued with convertible notes payable	4,676
Cashless exercise of options and warrants	222
Adoption of lease obligation and ROU asset	417,317
Fair value of beneficial conversion feature and original issue discount allocated to proceeds of convertible note payable		325,000
Fair value of warrants issued to extend maturity date of convertible notes payable		10,199
Fair value of warrants issued extend related party notes payable		337,466
Derivative liabilities written off with repayment of convertible notes payable		$ 160,850

Business and Business Presentat

Business and Business Presentation	3 Months Ended
	Mar. 31, 2019
Business and Business Presentation [Abstract]
BUSINESS AND BUSINESS PRESENTATION	NOTE 1 - BUSINESS AND BUSINESS PRESENTATION HealthLynked Corp., a Nevada corporation (the “Company” or “HLYK”) filed its Articles of Incorporation on August 4, 2014 with the Secretary of State of Nevada. On September 3, 2014 HLYK filed Amended Articles of Incorporation clarifying that the total authorized shares of 250,000,000 shares are broken up between 230,000,000 common shares and 20,000,000 preferred shares. On February 5, 2018, the Company filed an amendment with the Secretary of State of Nevada to increase the amount of authorized shares of common stock to 500,000,000 shares. On September 5, 2014, HLYK entered into a share exchange agreement (the “Share Exchange Agreement”) with Naples Women’s Center LLC (“NWC”), a Florida Limited Liability Company (“LLC”), acquiring 100% of the LLC membership units of NWC through the issuance of 50,000,000 shares of HLYK common stock to the members of NWC (the “Restructuring”). NWC is a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice located in Naples, Florida. On June 28, 2018, the Company formed wholly-owned subsidiary HLYK FL LLC (“Merger Sub”) to act as the acquiring entity in the acquisition of Hughes Center for Functional Medicine, P.A. (the “HCFM”). The acquisition of HCFM was completed on April 12, 2019. See “Note 15 – SUBSEQUENT EVENTS.” Merger Sub did not have any material activity since its inception or during the three months ended March 31, 2019. HLYK operates an online personal medical information and record archive system, the “HealthLynked Network”, which enables patients and doctors to keep track of medical information via the Internet in a cloud-based system. Patients complete a detailed online personal medical history including past surgical history, medications, allergies, and family history. Once this information is entered patients and their treating physicians are able to update the information as needed to provide a comprehensive medical history. These unaudited condensed consolidated financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the years ended December 31, 2018 and 2017, respectively, which are included in the Company’s Form 10-K filed with the United States Securities and Exchange Commission on April 1, 2019. The Company assumes that the users of the interim financial information herein have read, or have access to, the audited consolidated financial statements for the preceding period, and that the adequacy of additional disclosure needed for a fair presentation may be determined in that context. The results of operations for the three months ended March 31, 2019 are not necessarily indicative of results for the entire year ending December 31, 2019. All significant intercompany transactions and balances have been eliminated upon consolidation. In addition, certain amounts in the prior periods’ consolidated financial statements have been reclassified to conform to the current period presentation.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the presentation of the accompanying consolidated financial statements follows: Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("US GAAP"). All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about collection of accounts receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets, borrowing rate consideration for ROU lease assets including related lease liability and useful life of fixed assets. Adopted Accounting Pronouncements Effective January 1, 2019, the Company adopted Accounting Standards Update ("ASU") No. 2016-02, Leases ("ASU 2016-02") using the required modified retrospective approach. ASU 2016-02 requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. See discussion below under the caption "Leases" in this Note 2 and in Note 7 for more detail on the Company's accounting policy with respect to lease accounting. Effective January 1, 2019, the Company adopted ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees and supersedes the guidance in Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The . Patient Service Revenue Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected charges. The Company believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Company does not believe it is required to provide additional goods or services to the patient. The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company's policy, and/or implicit price concessions provided to uninsured patients. The Company determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: ● Medicare: ● Medicaid: ● Other: Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company's compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Cash and Cash Equivalents For financial statement purposes, the Company considers all highly-liquid investments with original maturities of three months or less to be cash and cash equivalents. Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers' accounts receivable during the related period which generally approximates 47% of total billings. Trade accounts receivable are recorded at this net amount. As of March 31, 2019 and December 31, 2018, the Company's gross accounts receivable were $227,943 and $244,956, respectively, and net accounts receivable were $106,905 and $114,884, respectively, based upon net reporting of accounts receivable. As of March 31, 2019 and December 31, 2018, the Company's allowance of doubtful accounts was $13,972 and $13,972, respectively. Leases Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as right-of-use ("ROU") assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company's condensed consolidated balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company's leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Adoption of ASU 2016-02 had an impact of $355,447 and $356,517 million on the Company's assets and liabilities, respectively, and had no material impact on cash provided by or used in operating, investing or financing activities on the Company's unaudited condensed consolidated statements of cash flows. Concentrations of Credit Risk The Company's financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company's revenue or accounts receivable. Generally, the Company's cash and cash equivalents are in checking accounts. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset's estimated fair value and its book value. There was no impairment as of March 31, 2019 and December 31, 2018. Convertible Notes Convertible notes are regarded as compound instruments, consisting of a liability component and an equity component. The component parts of compound instruments are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortized cost basis until extinguished upon conversion or at the instrument's maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized as additional paid-in capital and included in equity, net of income tax effects, and is not subsequently remeasured. After initial measurement, they are carried at amortized cost using the effective interest method. Convertible notes for which the maturity date has been extended and that qualify for debt extinguishment treatment are recorded at fair value on the extinguishment date and then revalue at the end of each reporting period, with the change recorded to the statement of operations under "Change in Fair Value of Debt." Derivative Financial Instruments The Company reviews the terms of convertible debt, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received, an immediate charge to income is recognized, in order to initially record the derivative instrument liabilities at their fair value. The discount from the face value of convertible debt instruments resulting from allocating some or all of the proceeds to the derivative instruments is amortized over the life of the instrument through periodic charges to income. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity's own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – ● Level 2 ● Level 3 The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs. Stock-Based Compensation The Company accounts for stock-based compensation under ASC 718 "Compensation – Stock Compensation" using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments. The Company uses the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes ("ASC 740-10") for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No Income Tax has been provided for the three months ended March 31, 2019, since the Company has sustained a loss for the period. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards (including the three months ended March 31, 2019) and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable. Recurring Fair Value Measurements The carrying value of the Company's financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, short-term borrowings, accounts payable, accrued liabilities, and derivative financial instruments approximated their fair value. Net Loss per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three months ended March 31, 2019 and 2018, the Company reported a net loss and excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of March 31, 2019 and December 31, 2018, potentially dilutive securities were comprised of (i) 45,058,874 and 46,161,463 warrants outstanding, respectively, (ii) 3,549,250 and 3,707,996 stock options outstanding, respectively, (iii) 10,346,866 and 15,517,111 shares issuable upon conversion of convertible notes, respectively, and (iv) 463,750 and 565,000 unissued shares subject to future vesting requirements granted pursuant to the Company's Employee Incentive Plan. Common stock awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of comprehensive loss in the same manner and charged to the same account as if such settlements had been made in cash. Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 11, Shareholders' Deficit Business Segments The Company uses the "management approach" to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company's reportable segments. Using the management approach, the Company determined that it has two operating segments: NWC (multi-specialty medical group including OB/GYN and General Practice) and HLYK (develops and markets the "HealthLynked Network," an online personal medical information and record archive system).

Going Concern Matters and Liqui

Going Concern Matters and Liquidity	3 Months Ended
	Mar. 31, 2019
Going Concern Matters and Liquidity [Abstract]
GOING CONCERN MATTERS AND LIQUIDITY	NOTE 3 – GOING CONCERN MATTERS AND LIQUIDITY As of March 31, 2019, the Company had a working capital deficit of $2,778,539 and accumulated deficit $11,561,772. For the three months ended March 31, 2019, the Company had a net loss of $1,060,717 and net cash used by operating activities of $600,393. Net cash used in investing activities was $4,302. Net cash provided by financing activities was $983,226, resulting principally from $833,226 proceeds from the sale of common stock and $150,000 net proceeds from the issuance of convertible notes. The Company’s cash balance and revenues generated are not currently sufficient and cannot be projected to cover its operating expenses for the next twelve months from the date of this report. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans include attempting to improve its business profitability and its ability to generate sufficient cash flow from its operations to meet its needs on a timely basis, obtaining additional working capital funds through equity and debt financing arrangements, and restructuring on-going operations to eliminate inefficiencies to raise cash balance in order to meet its anticipated cash requirements for the next twelve months from the date of this report. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures, working capital, and other requirements. Management intends to make every effort to identify and develop sources of funds. The outcome of these matters cannot be predicted at this time. There can be no assurance that any additional financings will be available to the Company on satisfactory terms and conditions, if at all. The ability of the Company to continue as a going concern is dependent upon its ability to raise additional capital and achieve profitable operations. The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. During July 2016, HLYK entered into an Investment Agreement (the “Investment Agreement”) pursuant to which the investor has agreed to purchase up to $3,000,000 of HLYK common stock over a three-year period starting upon registration of the underlying shares, with such shares put to the investor by the Company pursuant to a specified formula that limits the number of shares able to be put to the investor to the number equal to the average trading volume of the Company’s common shares for the ten consecutive trading days prior to the put notice being issued. During the three months ended March 31, 2019, the Company received $493,226 from the proceeds of the sale of 2,128,644 shares pursuant to the Investment Agreement.

Deferred Offering Costs and Pre

Deferred Offering Costs and Prepaid Expenses	3 Months Ended
	Mar. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
DEFERRED OFFERING COSTS AND PREPAID EXPENSES	NOTE 4 – DEFERRED OFFERING COSTS AND PREPAID EXPENSES Deferred Offering Costs On July 7, 2016, the Company entered into the Investment Agreement with an accredited investor, pursuant to which an accredited investor agreed to invest up to $3,000,000 to purchase the Company’s common stock, par value of $.0001 per share. The purchase price for such shares shall be 80% of the lowest volume weighted average price of the Company’s common stock during the five consecutive trading days prior to the date on which written notice is sent by the Company to the investor stating the number of shares that the Company is selling to the investor, subject to certain discounts and adjustments. Further, for each $50,000 that the investor tenders to the Company for the purchase of shares of common stock, the investor was to be granted warrants for the purchase of an equivalent number of shares of common stock. The warrants were to expire five (5) years from their respective grant dates and have an exercise price equal to 130% of the weighted average purchase price for the respective “$50,000 increment.” On March 22, 2017, the Company and the investor entered into an Amended Investment Agreement (the “Amended Investment Agreement”) whereby the parties agreed to modify the terms of the Investment Agreement by providing that in lieu of granting the investor warrants for each $50,000 that the investor tenders to the Company, the Company granted to the investor warrants to purchase an aggregate of 7,000,000 shares of common stock. The warrants have the following fixed exercise prices: (i) 4,000,000 shares at $0.25 per share; (ii) 2,000,000 shares at $0.50 per share; and (iii) 1,000,000 shares at $1.00 per share. The warrants also contain a “cashless exercise” provision and the shares underlying the warrants will not be registered. The fair value of the warrants was calculated using the Black-Scholes pricing model at $56,635, with the following assumptions: risk-free interest rate of 1.95%, expected life of 5 years, volatility of 40%, and expected dividend yield of zero. On June 7, 2017, the Company also granted warrants to purchase 200,000 shares at $0.25 per share, 100,000 shares at $0.50 per share and 50,000 shares at $1.00 per share to an advisor as a fee in connection with the Amended Investment Agreement. The fair value of the warrants was calculated using the Black-Scholes pricing model at $96,990, with the following assumptions: risk-free interest rate of 1.74%, expected life of 5 years, volatility of 40%, and expected dividend yield of zero. This fair value of the warrants described above was recorded as a deferred offering cost and will be amortized over the period during which the Company can access the financing, which begins the day after a registration statement registering shares underlying the Investment Agreement is declared effective by the United States Securities and Exchange Commission (the “SEC”), and ends 3 years from that date. On May 15, 2017, the SEC declared effective a registration statement registering shares underlying the Investment Agreement. During the three months ended March 31, 2019 and 2018, the Company recognized $12,802 and $12,802, respectively, in general and administrative expense related to the cost of the warrants. Prepaid Expenses On December 6, 2018, the Company granted additional three-year warrants to purchase 240,000 shares at an exercise price of $0.20 per share to two advisors for services to be provided over a three-month period. The fair value of the warrants was calculated using the Black-Scholes pricing model at $35,462, with the following assumptions: risk-free interest rate of 2.76%, expected life of 3 years, volatility of 285.22%, and expected dividend yield of zero. The Company recognized $25,611 and $-0- in the three months ended March 31, 2019 and 2018, respectively, to general and administrative expense related to the cost of the warrants.

Property, Plant, and Equipment

Property, Plant, and Equipment	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT, AND EQUIPMENT	NOTE 5 – PROPERTY, PLANT, AND EQUIPMENT Property, plant and equipment at March 31, 2019 and December 31, 2018 are as follows: March 31, December 31, 2019 2018 Capital Lease equipment $ 251,752 $ 343,492 Telephone equipment 12,308 12,308 Furniture, Transport and Office equipment 443,271 438,970 Total Property, plant and equipment 707,331 794,770 Less: accumulated depreciation (683,494 ) (752,173 ) Property, plant and equipment, net $ 23,837 $ 42,597 Depreciation expense during the three months ended three months ended March 31, 2019 and 2018 was $1,655 and $6,029, respectively.

Notes Payable and Other Amounts

Notes Payable and Other Amounts Due to Related Party	3 Months Ended
	Mar. 31, 2019
Notes Payable and Other Amounts Due to Related Party [Abstract]
NOTES PAYABLE AND OTHER AMOUNTS DUE TO RELATED PARTY	NOTE 6 – NOTES PAYABLE AND OTHER AMOUNTS DUE TO RELATED PARTY Amounts due to related parties as of March 31, 2019 and December 31, 2018 were comprised of the following: March 31, December 31, 2019 2018 Due to related party: Deferred compensation, Dr. Michael Dent $ 300,600 $ 300,600 Accrued interest payable to Dr. Michael Dent 145,676 129,117 Total due to related party $ 446,276 $ 429,717 Notes payable to related party: Notes payable to Dr. Michael Dent, current portion $ 678,329 $ 672,471 Notes Payable to Dr. Michael Dent Prior to August 2014, NWC was owned and controlled by the Company’s Chief Executive Officer, Dr. Michael Dent (“DMD”). DMD first provided an up to $175,000 unsecured note payable to the Company with a 0% interest rate. During 2013 the limit on the unsecured Note Payable was increased up to $500,000 and during 2014 it was increased to $750,000 with a maturity date of December 31, 2017. All principal and interest is due at maturity of the $750k DMD Note on December 31, 2019. Interest accrued on the $750k DMD Note as of March 31, 2019 and December 31, 2018 was $72,687 and $66,859, respectively. The carrying values of notes payable to Dr. Michael Dent as of March 31, 2019 and December 31, 2018 were as follows: Interest March 31, December 31, Inception Date Maturity Date Borrower Rate 2019 2018 January 12, 2017 January 13, 2019 HLYK 10 % $ 41,750 * $ 40,560 * January 18, 2017 January 19, 2019 HLYK 10 % 23,827 * 23,165 * January 24, 2017 January 15, 2019 HLYK 10 % 59,491 * 57,839 * February 9, 2017 February 10, 2019 HLYK 10 % 35,574 * 34,586 * April 20, 2017 April 21, 2019 HLYK 10 % 11,681 * 11,357 * June 15, 2017 June 16, 2019 HLYK 10 % 37,506 * 36,464 * August 17, 2017 August 18, 2018 HLYK 10 % 20,000 20,000 August 24, 2017 August 25, 2018 HLYK 10 % 37,500 37,500 September 7, 2017 September 8, 2018 HLYK 10 % 35,000 35,000 September 21, 2017 September 22, 2018 HLYK 10 % 26,500 26,500 September 29, 2017 September 30, 2018 HLYK 10 % 12,000 12,000 December 21, 2017 December 22, 2018 HLYK 10 % 14,000 14,000 January 8, 2018 January 9, 2019 HLYK 10 % 75,000 75,000 January 11, 2018 January 12, 2019 HLYK 10 % 9,000 9,000 January 26, 2018 January 27, 2019 HLYK 10 % 17,450 17,450 January 3, 2014 December 31, 2018 NWC 10 % 222,050 222,050 $ 678,329 $ 672,471 * - Denotes that note payable is carried at fair value On July 18, 2018, in connection with a $2,000,000 private placement by a third-party investor, Dr. Dent agreed to extend the maturity date on all of the above notes until December 31, 2019. Interest accrued on the above unsecured promissory notes as of March 31, 2019 and December 31, 2018 was $73,020 and $62,258, respectively. On February 12, 2018, the Company issued a warrant to purchase 6,678,462 shares of common stock to DMD as an inducement to (i) extend the maturity dates of up to $439,450 loaned by Dr. Dent to the Company in 2017 and 2018 in the form of unsecured promissory notes, including $75,000 loaned from Dr. Dent to the Company in January 2018 to allow the Company to retire an existing convertible promissory note payable to Power-up Lending Group Ltd. before such convertible promissory note became eligible for conversion, and (ii) provide continued loans to the Company. The warrant is immediately exercisable at an exercise price of $0.065 per share, subject to adjustment, and expires five years after the date of issuance. The fair value of the warrants was calculated using the Black-Scholes pricing model at $337,466, with the following assumptions: risk-free interest rate of 2.56%, expected life of 5 years, volatility of 268.90%, and expected dividend yield of zero. On March 28, 2018, DMD agreed to extend the maturity dates of promissory notes with an aggregate face value of $177,500, which were originally scheduled to mature before September 30, 2018, by one year from the original maturity date. Because the fair value of the warrants was greater than 10% of the present value of the remaining cash flows under the modified promissory notes, the transaction was treated as a debt extinguishment and reissuance of new debt instruments pursuant to the guidance of ASC 470-50 “Debt – Modifications and Extinguishments” (“ASC 470-50”). A loss on debt extinguishment was recorded in the amount of $348,938, equal to the fair value of the warrants of $337,466, plus the excess of $11,472 of the fair value of the reissued debt instruments over the carrying value of the existing debt instruments. The change in fair value of the reissued debt instruments subsequent to the reissuance date was $5,828 and $3,449 in the three months ended three months ended March 31, 2019 and 2018, respectively, and is included on the statement of operations in “Change in fair value of debt.” MedOffice Direct During 2017, the Company entered into an agreement with MedOffice Direct (“MOD”), a company majority-owned by the Company’s CEO and largest shareholder, Dr. Michael Dent, pursuant to which the Company agreed to pay rent to MOD in the amount of $2,040 per month for office space in MOD’s facility used by the Company and its employees for the period from January 1, 2017 through July 31, 2018. The agreement terminated on July 31, 2018. During the three months ended March 31, 2019 and 2018, the Company recognized rent expense to MOD in the amount of $-0- and $6,120, respectively, pursuant to this agreement. During 2017, the Company entered into a separate Marketing Agreement with MOD pursuant to which MOD agreed to market the HealthLynked Network to its physician practice clients, in exchange for a semi-annual fee of $25,000. This agreement was terminated effective April 1, 2018. During the three months ended March 31, 2019 and 2018, the Company recognized general and administrative expense in the amount of $-0- and $12,500, respectively, pursuant to this agreement. On July 1, 2018 HLYK and MOD signed a marketing and service agreement pursuant to which HLYK will include MOD offering as part of its product offering to Physicians and HLYK will receive 8% of revenue for new sales related to MOD products sold through the HLYK network.

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
LEASES	NOTE 7 – LEASES The Company has two operating leases for office space and equipment that expire in July 2020. The Company’s weighted-average remaining lease term relating to its operating leases is 1.3 years, with a weighted-average discount rate of 11.71%. The Company is also lessee in a capital equipment finance lease for medical equipment entered into in March 2015 and expiring in March 2020. The Company’s weighted-average remaining lease term relating to its financing lease is 1.0 years, with a weighted-average discount rate of 9.38%. The Company’s lease agreements generally do not provide an implicit borrowing rate, therefore an internal incremental borrowing rate is determined based on information available at lease commencement date for purposes of determining the present value of lease payments. The table below summarizes the Company’s lease-related assets and liabilities as of March 31, 2019: As of March 31, 2019 Operating Financing Total Leases Leases Leases Lease assets $ 338,126 $ 17,321 $ 355,447 Lease liabilities Lease liabilities (short term) $ 248,809 $ 17,321 $ 266,130 Lease liabilities (long term) 90,387 --- 90,387 Total lease liabilities $ 339,196 $ 17,321 $ 356,517 The Company incurred lease expense of $73,415 for the three months ended March 31, 2019, of which $68,828 related to operating leases and $4,587 related to financing leases. Maturities of operating lease liabilities were as follows as of March 31, 2019: Operating Capital Total Leases Leases Commitments 2019 (April through December) $ 206,098 $ 13,761 $ 219,859 2020 162,055 4,587 166,642 2021 --- --- --- 2022 --- --- --- 2023 --- --- --- Total lease payments 368,153 18,348 386,501 Less interest (28,957 ) (1,027 ) (29,984 ) Present value of lease liabilities $ 339,196 $ 17,321 $ 356,517

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 8 – NOTES PAYABLE On December 20, 2017, the Company entered into a Merchant Cash Advance Factoring Agreement (“MCA”) with Power Up Lending Group, Ltd. (the “PULG”) pursuant to which the Company received an advance of $75,000 before closing fees (the “December MCA”). The Company is required to repay the advance, which acts like an ordinary note payable, at the rate of $4,048 per week until the balance of $102,000, which was scheduled for June 2018. At inception, the Company recognized a note payable in the amount of $102,000 and a discount against the note payable of $28,500. The discount was being amortized over the life of the instrument. During the three months ended March 31, 2019 and 2018, the Company made installment payments of $-0- and $52,619, respectively, on the December MCA. During the three months ended March 31, 2019 and 2018, the Company recognized amortization of the discount in the amount of $-0- and $14,574, respectively. The December MCA was repaid on June 1, 2018.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 9 –CONVERTIBLE NOTES PAYABLE Convertible notes payable as of March 31, 2019 and December 31, 2018 are comprised of the following: March 31, December 31, 2019 2018 $550k Note - July 2016 $ 611,651 * $ 594,813 $50k Note - July 2016 62,019 * 60,312 $111k Note - May 2017 128,734 * 125,190 $171.5k Note - October 2017 --- 186,472 $103k Note I - October 2018 103,000 103,000 $103k Note II - November 2018 103,000 103,000 $153k Note - November 2018 153,000 153,000 $103k Note III - December 2018 103,000 103,000 $78k Note I - January 2019 78,000 --- $78k Note II - January 2019 78,000 --- 1,420,404 1,428,787 Less: unamortized discount (363,089 ) (386,473 ) Convertible notes payable, net of original issue discount and debt discount 1,057,315 1,042,314 * - Denotes that convertible note payable is carried at fair value Amortization expense and interest expense recognized on each convertible note outstanding during the three months ended March 31, 2019 and 2018 were as follows: Amortization of Debt Discount Interest Expanse Three Months Ended Three Months Ended 2019 2018 2019 2018 $550k Note - July 2016 $ --- $ --- $ 8,137 $ 8,137 $50k Note - July 2016 --- --- 1,233 1,233 $111k Note - May 2017 --- 11,011 4,078 4,078 $53k Note - July 2017 --- 1,520 --- 116 $35k Note - September 2017 --- 7,972 --- 614 $55k Note - September 2017 --- 10,849 --- 1,085 $53k Note II - October 2017 --- 17,036 --- 1,307 $171.5k Note - October 2017 --- 42,404 1,785 4,229 $57.8k Note - January 2018 --- 13,923 --- 1,392 $112.8k Note - February 2018 --- 17,608 --- 1,761 $83k Note - February 2018 --- 10,460 --- 1,046 $105k Note - March 2018 --- 7,479 --- 748 $103k Note I - October 2018 32,526 --- 2,540 --- $103k Note II - November 2018 31,856 --- 2,540 --- $153k Note - November 2018 50,440 --- 3,773 --- $103k Note III - December 2018 25,397 --- 2,540 --- $78k Note I - January 2019 21,714 --- 1,624 --- $78k Note II - January 2019 17,451 --- 1,410 --- $ 179,384 $ 140,262 $ 29,660 $ 25,746 Unamortized debt discount on outstanding convertible notes payable as of March 31, 2019 and December 31, 2018 are comprised of the following: Unamortized Discount as of March 31, December 31, 2019 2018 $103k Note I - October 2018 $ 43,730 $ 76,256 $103k Note II - November 2018 53,801 85,656 $153k Note - November 2018 79,022 129,462 $103k Note III - December 2018 69,701 95,099 $78k Note I - January 2019 56,286 --- $78k Note II - January 2019 60,549 --- $ 363,089 $ 386,473 Certain of our convertible notes payable are also carried at fair value and revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” The changes in fair value during the three months ended March 31, 2019 and 2018 on such instruments were as follows: Change in Fair Value of Debt Fair Value of Debt as of Three Months Ended March 31, March 31, December 31, 2019 2018 2019 2018 $550k Note - July 2016 $ 16,838 $ 46,298 $ 611,651 $ 594,813 $50k Note - July 2016 1,707 8,199 62,019 60,312 $111k Note - May 2017 3,544 8,815 128,734 125,190 $171.5k Note - October 2017 1,781 --- --- 186,472 $ 23,870 $ 63,312 $ 802,404 $ 966,787 Convertible Notes Payable ($550,000) – July 2016 On July 7, 2016, the Company entered into a 6% fixed convertible secured promissory note with an investor with a face value of $550,000 (the “$550k Note”). The $550k Note is convertible into shares of the Company’s common stock at the discretion of the note holder at a fixed price of $0.08 per share, or 6,875,000 of the Company’s common shares, and is secured by all of the Company’s assets. The Company received $500,000 net proceeds from the note after a $50,000 original issue discount. The $550k Note was originally scheduled to mature on April 11, 2017, but the maturity date was extended to July 7, 2018 during August 2017 and to December 31, 2019 during July 2018. The discount from the original issue discount, warrants and embedded conversion feature (“ECF”) associated with the $550k Note was amortized over the original life of the note. The $550k Note is carried at fair value due to an extinguishment and reissuance recorded in 2017 and is revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” Convertible Notes Payable ($50,000) – July 2016 On July 7, 2016, the Company entered into a 10% fixed convertible commitment fee promissory note with an investor with a face value of $50,000 (the “$50k Note”). The $50k Note was originally scheduled to mature on April 11, 2017, but the maturity date was extended to July 11, 2018 during August 2017 and to December 31, 2019 during July 2018. The $50k note was issued as a commitment fee payable to the Investment Agreement investor in exchange for the investor’s commitment to enter into the Investment Agreement, subject to registration of the shares underlying the Investment Agreement. The $50k Note is convertible into shares of the Company’s common stock at the discretion of the note holder at a fixed price of $0.10 per share, or 500,000 of the Company’s common shares. The $50k Note is carried at fair value due to an extinguishment and reissuance recorded in 2017 and is revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” Convertible Notes Payable ($111,000) – May 2017 On May 22, 2017, the Company entered into a 10% fixed convertible secured promissory note with an investor with a face value of $111,000 (the “$111k Note”). The $111k Note is convertible into shares of the Company’s common stock at the discretion of the note holder at a fixed price of $0.35 per share, or 317,143 of the Company’s common shares, and is secured by all of the Company’s assets. The Company received $100,000 net proceeds from the note after an $11,000 original issue discount. At inception, the investors were also granted a five-year warrant to purchase 133,333 shares of the Company’s common stock at an exercise price of $0.75 per share. On March 28, 2018, in exchange for a five-year warrant to purchase 125,000 shares of HLYK common stock at an exercise price of $0.05 per share, the holder of the $111k Note agreed to extend the maturity date from the original date of January 22, 2018 until July 11, 2018. The fair value of the warrants using Black/Scholes was $10,199 with the following assumptions: risk-free interest rate of 2.59%, expected life of 5 years, volatility of 578.45%, and expected dividend yield of zero. The issuance of the warrants in exchange for the maturity extension was treated as an extinguishment and reissuance of existing debt pursuant to the guidance of ASC 470-50. Accordingly, the $111k Note is carried at fair value and is revalued at each period end, with changes to fair value recorded to the statement of operations under “Change in Fair Value of Debt.” During July 2018, the maturity date of the $111k Note was further extended until December 31, 2017. Convertible Notes Payable ($53,000) – July 2017 On July 10, 2017, the Company entered into a securities purchase agreement for the sale of a $53,000 convertible note (the “$53k Note”) to PULG. On January 8, 2018, the Company prepaid the balance on the $53k Note, including accrued interest, for a one-time cash payment of $74,922. The Company recognized a gain on debt extinguishment in the three months ended March 31, 2018 in connection with the repayment, as follows: Cash repayment $ 74,922 Less face value of convertible note payable retired (53,000 ) Less carrying value of derivative financial instruments arising from ECF (53,893 ) Less accrued interest (2,644 ) Plus carrying value of discount at extinguishment 18,427 Gain on extinguishment of debt $ (16,188 ) Convertible Notes Payable ($35,000) – September 2017 On September 7, 2017, the Company entered into a securities purchase agreement for the sale of a $35,000 convertible note (the “$35k Note”) to PULG. On March 5, 2018, the Company prepaid the balance on the $35k Note, including accrued interest, for a one-time cash payment of $49,502. The Company recognized a gain on debt extinguishment in the three months ended March 31, 2018 in connection with the repayment, as follows: Cash repayment $ 49,502 Less face value of convertible note payable retired (35,000 ) Less carrying value of derivative financial instruments arising from ECF (37,269 ) Less accrued interest (1,716 ) Plus carrying value of discount at extinguishment 12,705 Gain on extinguishment of debt $ (11,778 ) Convertible Notes Payable ($55,000) – September 2017 On September 11, 2017, the Company entered into a securities purchase agreement for the sale of a $55,000 convertible note (the “$55k Note”) to Crown Bridge Partners LLC. On March 13, 2018, the Company prepaid the balance on the $55k Note, including accrued interest, for a one-time cash payment of $85,258. The Company recognized a gain on debt extinguishment in the three months ended March 31, 2018 in connection with the repayment, as follows: Cash repayment $ 85,258 Less face value of convertible note payable retired (55,000 ) Less carrying value of derivative financial instruments arising from ECF (69,687 ) Less accrued interest (2,759 ) Plus carrying value of discount at extinguishment 27,425 Gain on extinguishment of debt $ (14,763 ) Convertible Notes Payable ($171,500) – October 2017 On October 27, 2017, the Company entered into a securities purchase agreement for the sale of a $171,500 convertible note (the “$171.5k Note”) to an individual lender. The $171.5k Note included a $21,500 original issue discount, for net proceeds of $150,000. The $171.5k Note had an interest rate of 10% and a default interest rate of 22% and matures on October 26, 2018. The $171.5k Note was convertible into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 35% discount to the lowest closing bid price during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the $171.5k Note, 300% of the outstanding principal and any interest due amount was immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the $171.5k Note, 150% of the outstanding principal and any interest due amount was immediately due. During three months ended March 31, 2019, the holder of the $171.5k Note converted the entire principal balance of $171,500 into 2,512,821 shares of Company common stock. Convertible Notes Payable ($57,750) – January 2018 On January 2, 2018, the Company entered into a securities purchase agreement for the sale of a $57,750 convertible note (the “$58k Note”). The transaction closed on January 3, 2018. The $58k Note included a $5,250 original issue discount and $2,500 fee for net proceeds of $50,000. The $58k Note had an interest rate of 10% and a default interest rate of 18% and was scheduled to mature on January 2, 2019. The $58k Note was convertible into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 28% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. On June 26, 2018, the holder agreed, without consideration, to reduce the discount to 28% of the volume weighted average price of the Company’s common stock for the 10 days prior to the conversion date. During third and fourth quarter of 2018, the holder of the $58k Note converted the entire principal balance of $57,750, as well as accrued interest in the amount of $3,786, into 384,839 shares of Company common stock. Accrued but unpaid interest of $21,990 was outstanding as of March 31, 2019. Convertible Notes Payable ($112,750) – February 2018 On February 2, 2018, the Company entered into a securities purchase agreement for the sale of a $112,750 convertible note (the “$113k Note”). The transaction closed on February 8, 2018. The $113k Note included $12,750 fees for net proceeds of $100,000. The $113k Note has an interest rate of 10% and a default interest rate of 24% and matures on February 2, 2019. The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the Note, 200% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due. On August 7, 2018, the Company prepaid the balance on the $113k Note, including accrued interest, for a one-time cash payment of $151,536. In connection with the extinguishment, the Company also issued the holder a 3-year warrant to purchase 100,000 shares of Company common stock at an exercise price of $0.25. The fair value of the warrant was $50,614. The Company recognized a gain on debt extinguishment of $2,054 in the third quarter of 2018 in connection with the repayment Convertible Notes Payable ($83,000) – February 2018 On February 13, 2018, the Company entered into a securities purchase agreement for the sale of a $83,000 convertible note (the “$83k Note”). The transaction closed on February 21, 2018. The $83k Note included $8,000 fees for net proceeds of $75,000. The $83k Note has an interest rate of 10% and a default interest rate of 24% and matures on February 13, 2019. The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default, 200% of the outstanding principal and any interest due amount shall be immediately due. On August 16, 2018, the Company prepaid the balance on the $83k Note, including accrued interest, for a one-time cash payment of $111,596. In connection with the extinguishment, the Company also issued the holder a 5-year warrant to purchase 237,143 shares of Company common stock at an exercise price of $0.35. The fair value of the warrant was $92,400. The Company recognized a loss on debt extinguishment of $51,251 in the third quarter of 2018 in connection with the repayment. Convertible Notes Payable ($105,000) – March 2018 On March 5, 2018, the Company entered into a securities purchase agreement for the sale of a $105,000 convertible note (the “$105k Note”). The transaction closed on March 12, 2018. The $105k Note included $5,000 fees for net proceeds of $100,000. The $105k Note has an interest rate of 10% and a default interest rate of 24% and matures on March 5, 2019. The $113k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 9.9% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default, 110-150% of the outstanding principal and any interest due amount shall be immediately due, depending on the nature of the breach. On August 30, 2018, the Company prepaid the balance on the $105k Note, including accrued interest, for a one-time cash payment of $140,697. The Company recognized a gain on debt extinguishment of $51,804 in the third quarter of 2018 in connection with the repayment. Convertible Notes Payable ($78,000) – January 2019 On January 14, 2019, the Company entered into a securities purchase agreement for the sale of a $78,000 convertible note (the “$78k Note”). The $78k Note included $3,000 fees for net proceeds of $75,000. The $78k Note has an interest rate of 10% and a default interest rate of 24% and matures on October 14, 2019. The $78k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 25% discount to the lowest bid or trading price of the Company’s common stock during the ten (10) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due. The fair value of the ECF of the $78k Note was calculated using the Black-Scholes pricing model at $78,088, with the following assumptions: risk-free interest rate of 2.57%, expected life of 0.75 years, volatility of 243.61%, and expected dividend yield of zero. In connection with the $78k Note, the Company also issued to the holder 28,000 shares of Company common stock valued at $4,676, which was recorded to equity. Because the fair value of the ECF exceeded the net proceeds from the $78k Note, a charge was recorded to “Financing cost” for the excess of the fair value of the fair value of the ECF of $78,088 and the common shares issued of $4,676 over the net proceeds from the note of $75,000, for a net charge of $7,764. The ECF qualifies for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The final allocation of the proceeds at inception was as follows: Embedded conversion feature $ 78,088 Original issue discount and fees 3,000 Fair value of shares recorded to equity 4,676 Financing cost (7,764 ) Convertible note --- Gross proceeds $ 78,000 Convertible Notes Payable ($78,000) – January 2019 On January 24, 2018, the Company entered into a securities purchase agreement for the sale of a $78,000 convertible note (the “$78k Note II”). The $78k Note II included $3,000 fees for net proceeds of $75,000. The $78k Note II has an interest rate of 10% and a default interest rate of 22% and matures on November 15, 2019. The $78k Note II may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the lowest bid or trading price of the Company’s common stock during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due. The fair value of the ECF of the $78k Note II was calculated using the Black-Scholes pricing model at $101,139, with the following assumptions: risk-free interest rate of 2.58%, expected life of 0.81 years, volatility of 243.03%, and expected dividend yield of zero. Because the fair value of the ECF exceeded the net proceeds from the $78k Note II, a charge was recorded to “Financing cost” for the excess of the fair value of the fair value of the ECF of $101,139 over the net proceeds from the note of $75,000, for a net charge of $26,139. The ECF qualifies for derivative accounting and bifurcation under ASC 815, “Derivatives and Hedging.” The final allocation of the proceeds at inception was as follows: Embedded conversion feature $ 101,139 Original issue discount and fees 3,000 Financing cost (26,139 ) Convertible note --- Gross proceeds $ 78,000

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS	NOTE 10 – DERIVATIVE FINANCIAL INSTRUMENTS Derivative financial instruments are comprised of the fair value of conversion features embedded in convertible promissory notes for which the conversion rate is not fixed, but instead is adjusted based on a discount to the market price of the Company’s common stock. The fair market value of the derivative liabilities was calculated at inception of each convertible promissory notes for which the conversion rate is not fixed and allocated to the respective convertible notes, with any excess recorded as a charge to “Financing cost.” The derivative financial instruments are then revalued at the end of each period, with the change in value recorded to “Change in fair value of on derivative financial instruments.” Derivative financial instruments and changes thereto recorded in the three months ended March 31, 2019 include the following: Change in Fair Value Inception of Fair Value Conversion Fair Value as of Derivative of Derivative of Derivative as of December 31, Financial Financial Financial March 31, 2018 Instruments Instruments Instruments 2019 $171.5k Note - October 2017 $ 229,902 $ --- $ (22,720 ) $ (207,182 ) $ --- $103k Note I - October 2018 131,617 --- (33,857 ) --- 97,760 $103k Note II - November 2018 135,845 --- (32,378 ) --- 103,467 $153k Note - November 2018 157,426 --- (45,408 ) --- 112,018 $103k Note III - December 2018 145,650 --- (28,544 ) --- 117,106 $78k Note I - January 2019 --- 78,088 (14,573 ) --- 63,515 $78k Note II - January 2019 --- 101,142 (14,153 ) --- 86,989 $ 800,440 $ 179,230 $ (191,633 ) $ (207,182 ) $ 580,855 Derivative financial instruments and changes thereto recorded in the three months ended March 31, 2018 include the following: Change in Fair Value Inception of Fair Value Write off Fair Value as of Derivative of Derivative Derivative as of December 31, Financial Financial Financial March 31, 2017 Instruments Instruments Instruments 2018 (audited) $53k Note - July 2017 $ 48,876 $ --- $ 5,017 $ (53,893 ) $ --- $35k Note - September 2017 36,161 --- 1,108 (37,269 ) --- $55k Note - September 2017 64,656 --- 5,032 (69,688 ) --- $53k Note #2 - October 2017 58,216 --- 617 --- 58,833 $171.5k Note - October 2017 190,580 --- 11,979 --- 202,559 $57.8k Note - January 2018 --- 82,653 (2,905 ) --- 79,748 $112.8k Note - February 2018 --- 161,527 (2,371 ) --- 159,156 $83k Note - February 2018 --- 119,512 (1,525 ) --- 117,987 $105k Note - March 2018 --- 153,371 (2,331 ) --- 151,040 $ 398,489 $ 517,063 $ 14,621 $ (160,850 ) $ 769,323 During the three months ended March 31, 2019, the $171.5k Note was converted in full into common shares by the holder. During the three months ended March 31, 2018, three convertible notes were repaid in full for cash. Accordingly, the derivative financial instruments associated with the ECFs of these convertible notes were written off in connection with the extinguishment of each convertible note. Fair market value of the derivative financial instruments is measured using the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 2.40% to 2.73%, expected life of 0.33 to 1.00 years, volatility of 202.73% to 293.97%, and expected dividend yield of zero. The entire amount of derivative instrument liabilities is classified as current due to the fact that settlement of the derivative instruments could be required within twelve months of the balance sheet date.

Shareholders' Deficit

Shareholders' Deficit	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
SHAREHOLDERS' DEFICIT	NOTE 11 – SHAREHOLDERS’ DEFICIT Sales of Common Stock On January 11, 2018, the Company sold 588,235 shares of common stock in a private placement transaction to an investor and received $50,000 in proceeds from the sale. The shares were issued at a share price of $0.085 per share. In connection with the stock sales, the Company also issued 588,235 five-year warrants to purchase shares of common stock at an exercise price of $0.15 per share. On February 28, 2018, the Company sold 2,352,942 shares of common stock in private placement transactions to two investors and received $200,000 in proceeds from the sale. The shares were issued at a share price of $0.085 per share. In connection with the stock sales, the Company also issued 1,764,706 five-year warrants to purchase shares of common stock at an exercise price of $0.15 per share. During the three months ended March 31, 2019, the Company sold 1,133,334 shares of common stock in two separate private placement transactions and received $340,000 in proceeds from the sales. The shares were issued at a share price of $0.30 per share. In connection with the stock sale, we also issued 566,667 five-year warrants to purchase shares of common stock at an exercise price of $0.40 per share and 250,000 three-year warrants to purchase shares of common stock at an exercise price of $0.50 per share. During the three months ended March 31, 2019 and 2018, the Company issued 2,128,644 and 42,969 common shares, respectively, pursuant to draws made by the Company under the Investment Agreement and received an aggregate of $493,226 and $1,563, respectively, in net proceeds from the draws. Common Stock Issuable As of March 31, 2019 and December 31, 2018, the Company was obligated to issue 205,301 and 114,080 shares of common stock, respectively, in exchange for professional services provided by two third party consultants. During the three months ended March 31, 2019 and 2018, the Company recognized expense related to shares earned by the consultants of $46,098 and $5,287, respectively. Stock Warrants Transactions involving our stock warrants during the three months ended three months ended March 31, 2019 and 2018 are summarized as follows: 2019 2018 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 46,161,463 $ 0.18 20,526,387 $ 0.23 Granted during the period 996,667 $ 0.42 9,156,403 $ 0.09 Exercised during the period (2,099,256 ) $ 0.00 --- $ --- Terminated during the period --- $ --- --- $ --- Outstanding at end of the period 45,058,874 $ 0.19 29,682,790 $ 0.19 Exercisable at end of the period 45,058,874 $ 0.19 29,682,790 $ 0.19 Weighted average remaining life 3.5 years 4.9 years The following table summarizes information about the Company’s stock warrants outstanding as of March 31, 2019: Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.0001 to 0.09 18,157,768 3.6 $ 0.06 18,157,768 $ 0.06 $ 0.10 to 0.24 14,520,441 3.8 $ 0.19 14,520,441 $ 0.19 $ 0.25 to 0.49 8,440,665 3.3 $ 0.29 8,440,665 $ 0.29 $ 0.50 to 1.00 3,940,000 2.9 $ 0.64 3,940,000 $ 0.64 $ 0.05 to 1.00 45,058,874 3.5 $ 0.20 45,058,874 $ 0.20 During the three months ended March 31, 2019, the Company issued 996,667 warrants. The fair value of the warrant was calculated using the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 2.44% to 2.52%, expected life of 3 to 5 years, volatility of 212.96% to 216.35%, and expected dividend yield of zero. The aggregate grant date fair value of warrants issued during the three months ended March 31, 2019 was $294,707. During the three months ended March 31, 2018, the Company issued 9,156,403 warrants. The fair value of the warrant was calculated using the Black-Scholes pricing model with the following assumptions: risk-free interest rate of 2.23% to 2.65%, expected life of 5 years, volatility of 261.18 - 278.45%, and expected dividend yield of zero. The aggregate grant date fair value of warrants issued during the three months ended March 31, 2018 was $582,311. Employee Equity Incentive Plan On January 1, 2016, the Company instituted the Employee Equity Incentive Plan (the “EIP”) for the purpose of having equity awards available to allow for equity participation by its employees. The EIP allows for the issuance of up to 15,503,680 shares of the Company’s common stock to employees, which may be issued in the form of stock options, stock appreciation rights, or restricted shares. The EIP is governed by the Company’s board, or a committee that may be appointed by the board in the future. The following table summarizes the status of shares issued and outstanding under the EIP outstanding as of and for the three months ended March 31, 2019 and 2018: 2019 2018 Outstanding at beginning of the period 1,738,750 1,498,750 Granted during the period 61,563 --- Terminated during the period --- --- Outstanding at end of the period 1,800,313 1,498,750 Shares vested at period-end 1,336,563 1,058,750 Weighted average grant date fair value of shares granted during the period $ 0.26 $ --- Aggregate grant date fair value of shares granted during the period $ 12,805 $ --- Shares available for grant pursuant to EIP at period-end 10,154,118 11,654,934 Total stock-based compensation recognized for grants under the EIP was $32,779 and $2,435 during the three months ended March 31, 2019 and 2018. Total unrecognized stock compensation related to these grants was $92,918 as of March 31, 2019. A summary of the status of non-vested shares issued pursuant to the EIP as of and for the three months ended March 31, 2019 and 2018 is presented below: 2019 2018 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Nonvested at beginning of period 540,000 $ 0.16 628,750 $ 0.05 Granted --- $ --- --- $ --- Vested (76,250 ) $ 0.04 (188,750 ) $ 0.04 Forfeited --- $ --- --- $ --- Nonvested at end of period 463,750 $ 0.18 440,000 $ 0.05 Employee Stock Options The following table summarizes the status of options outstanding as of and for the three months ended March 31, 2019 and 2018: 2019 2018 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 3,707,996 $ 0.18 2,349,996 $ 0.12 Granted during the period 591,250 $ 0.26 --- $ --- Exercised during the period (154,166 ) $ 0.20 --- $ --- Forfeited during the period (595,830 ) $ 0.20 --- $ --- Outstanding at end of the period 3,549,250 $ 0.19 2,349,996 $ 0.12 Options exercisable at period-end 1,261,000 637,500 Weighted average remaining life (in years) 8.2 8.4 Weighted average grant date fair value of options granted during the period $ 0.21 $ --- Options available for grant at period-end 10,154,118 11,654,934 The following table summarizes information about the Company’s stock options outstanding as of March 31, 2019: Options Outstanding Options Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ --- to 0.10 1,733,000 6.9 $ 0.08 1,183,000 0.08 $ 0.11 to 0.31 1,816,250 9.5 $ 0.29 78,000 0.31 $ 0.08 to 0.31 3,549,250 8.2 $ 0.19 1,261,000 $ 0.10 Total stock-based compensation recognized related to option grants was $28,456 and $2,354 during the three months ended March 31, 2019 and 2018, respectively. A summary of the status of non-vested options issued pursuant to the EIP as of and for the three months ended March 31, 2019 and 2018 is presented below: 2019 2018 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Nonvested at beginning of period 2,332,413 $ 0.13 1,774,996 $ 0.03 Granted 591,250 $ 0.21 --- $ --- Vested (39,583 ) $ 0.03 (62,500 ) $ 0.03 Forfeited (595,830 ) $ 0.02 --- $ --- Nonvested at end of period 2,288,250 $ 0.18 1,712,496 $ 0.03

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 – COMMITMENTS AND CONTINGENCIES Service contracts The Company carries various service contracts on its office buildings & certain copier equipment for repairs, maintenance and inspections. All contracts are short term and can be cancelled. Litigation From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not aware of any such legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results. Leases Maturities of operating lease liabilities were as follows as of March 31, 2019: Operating Capital Total Leases Leases Commitments 2019 (April through December) $ 206,098 $ 13,761 $ 219,859 2020 162,055 4,587 166,642 2021 --- --- --- 2022 --- --- --- 2023 --- --- --- Total lease payments 368,153 18,348 386,501 Less interest (28,957 ) (1,027 ) (29,984 ) Present value of lease liabilities $ 339,196 $ 17,321 $ 356,517 Employment/Consulting Agreements The Company has employment agreements with each of its four physicians. The agreements generally call for a fixed salary at the beginning of the contract with a transaction to performance-based pay later in the contract. The contracts expire at various times through 2019, with early termination available upon a notice period of 30-90 days during which compensation is paid to the physician but NWC has no further severance obligation. On July 1, 2016, HLYK entered into an employment agreement with Dr. Michael Dent, Chief Executive Officer and a member of the Board of Directors. Dr. Dent’s employment agreement continues until terminated by Dr. Dent or HLYK. If Dr. Dent’s employment is terminated by HLYK (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Dr. Dent will be entitled to severance in an amount equal to 12 months of his then-current annual base salary, as well as the pro-rata portion of any bonus that would be due and payable to him. In the event that Dr. Dent terminates the employment agreement, he shall be entitled to any accrued but unpaid salary and other benefits up to and including the date of termination, and the pro-rata portion of any unvested time-based options up until the date of termination. On July 1, 2016, HLYK entered into an agreement with Mr. George O’Leary, the Company’s Chief Financial Officer and a member of the Board of Directors, extending his prior agreement with the Company. Mr. O’Leary’s employment agreement continues until terminated by Mr. O’Leary or HLYK. If Mr. O’Leary employment is terminated by HLYK (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Mr. O’Leary will be entitled to receive his base salary and the Company shall maintain his employee benefits for a period of twelve (12) months beginning on the date of termination. In the event that Mr. O’Leary terminates the agreement, he shall be entitled to any accrued by unpaid salary and other benefits up to and including the date of termination. On July 1, 2018, HLYK and Mr. O’Leary entered into an Extension Letter Agreement pursuant to which Mr. O’Leary was increased to full time employment (previously half-time) and agreed to extend the term of his employment to September 30, 2022. In addition to a base salary, the extension provides Mr. O’Leary with certain performance-based cash bonuses, stock grants, and stock option grants.

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 13 – SEGMENT REPORTING The Company has two reportable segments: NWC and HLYK. NWC is a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice. The practice’s office is located in Naples, Florida. HLYK plans to operate an online personal medical information and record archive system, the “HealthLynked Network”, which will enable patients and doctors to keep track of medical information via the Internet in a cloud-based system. Patients will complete a detailed online personal medical history including past surgical history, medications, allergies, and family history. Once this information is entered patients and their treating physicians will be able to update the information as needed to provide a comprehensive medical history. The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. Segment information for the three months ended March 31, 2019 and 2018 was as follows: Three Months Ended March 31, 2019 Three Months Ended March 31, 2018 NWC HLYK Total NWC HLYK Total Revenue Patient service revenue, net $ 464,990 $ --- $ 464,990 $ 645,639 $ --- $ 645,639 Operating Expenses Salaries and benefits 350,238 178,987 529,225 403,055 157,801 560,856 General and administrative 242,600 514,756 757,356 225,652 349,176 574,828 Depreciation and amortization 1,060 595 1,655 5,574 455 6,029 Total Operating Expenses 593,898 694,338 1,288,236 634,281 507,432 1,141,713 Loss from operations $ (128,908 ) $ (694,338 ) $ (823,246 ) $ 11,358 $ (507,432 ) $ (496,074 ) Other Segment Information Interest expense $ 5,828 $ 40,494 $ 46,322 $ 5,697 $ 34,650 $ 40,347 Loss on extinguishment of debt $ --- $ 139,798 $ 139,798 $ --- $ 325,223 $ 325,223 Financing cost $ --- $ 33,903 $ 33,903 $ --- $ 192,062 $ 192,062 Amortization of original issue and debt discounts on convertible notes $ --- $ 179,384 $ 179,384 $ --- $ 154,835 $ 154,835 Change in fair value of debt $ --- $ 29,697 $ 29,697 $ --- $ 57,946 $ 57,946 Change in fair value of derivative financial instruments $ --- $ (191,633 ) $ (191,633 ) $ --- $ 14,621 $ 14,621 March 31, 2019 December 31, 2018 Identifiable assets $ 520,535 $ 565,751 $ 1,086,286 $ 184,912 $ 242,451 $ 427,363 During the three months ended March 31, 2019 and 2018, HLYK recognized revenue of $1,941 and $6,888, respectively, related to subscription revenue billed to and paid for by NWC physicians for access to the HealthLynked Network. The revenue for HLYK and related expense for NWC were eliminated on consolidation.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	NOTE 14 – FAIR VALUE OF FINANCIAL INSTRUMENTS The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate their respective fair values due to the short-term nature of such instruments. The Company measures certain financial instruments at fair value on a recurring basis, including certain convertible notes payable and related party loans which were extinguished and reissued and are therefore subject to fair value measurement, as well as derivative financial instruments arising from conversion features embedded in convertible promissory notes for which the conversion rate is not fixed. All financial instruments carried at fair value fall within Level 3 of the fair value hierarchy as their value is based on unobservable inputs. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of March 31, 2019 and December 31, 2018: As of March 31, 2019 Total Level 1 Level 2 Level 3 Fair Value Convertible notes payable $ --- $ --- $ 802,404 $ 802,404 Notes payable to related party --- --- 209,829 209,829 Derivative financial instruments --- --- 580,855 580,855 Total $ --- $ --- $ 1,593,088 $ 1,593,088 As of December 31, 2018 Total Level 1 Level 2 Level 3 Fair Value Convertible notes payable $ --- $ --- $ 780,315 $ 780,315 Notes payable to related party --- --- 203,971 203,971 Derivative financial instruments --- --- 800,440 800,440 Total $ --- $ --- $ 1,784,726 $ 1,784,726 The changes in Level 3 financial instruments that are measured at fair value on a recurring basis during the three months ended March 31, 2019 and 2018 were as follows: Three Months Ended 2019 2018 Convertible notes payable $ (23,869 ) $ (54,497 ) Notes payable to related party (5,828 ) (3,449 ) Derivative financial instruments 191,633 (14,621 ) Total $ 161,936 $ (72,567 )

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 – SUBSEQUENT EVENTS On April 12, 2019 the Company acquired a 100% interest in HCFM, a medical practice engaged in improving the health of its patients through individualized and integrative health care. Under the terms of acquisition, we paid HCFM shareholders $500,000 in cash and issued 3,968,254 shares of our common stock along with an earn out provision of $500,000 that may be earned based on the performance of HCFM in fiscal years ended December 31, 2019-21. The total consideration represents a transaction value of approximately $2 million. The Company funded the acquisition of HCFM through available cash and the issuance of restricted common shares. The Company plans to account for the transaction as an acquisition of a business pursuant to ASC 805, “Business Combinations” (“ASC 805”). The Company is currently engaged in establishing the acquisition date fair value and allocating the fair value across the specific assets and liabilities acquired pursuant to the requirements of ASC 805. The Company expects that the required enterprise valuation of the acquisition and purchase price allocation will be completed by and included in our financial statements reporting our second quarter activity as of June 30, 2019. On April 3, 2019, the Company entered into a securities purchase agreement for the sale of a $103,000 convertible note. The note included $3,000 fees for net proceeds of $100,000. The note has an interest rate of 10% and a default interest rate of 22%, matures on February 28, 2020 and may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the lowest bid or trading price of the Company’s common stock during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due. On April 4, 2019, the Company repaid a convertible note dated October 18, 2018 with a face value of $103,000, along with interest accrued thereon, for a one-time cash payment of $134,500. On April 11, 2019, the Company entered into securities purchase agreements for the sale of two identical convertible notes with an aggregate face value of $209,000. The notes included $9,000 fees for net proceeds of $200,000. The notes have an interest rate of 10% and a default interest rate of 22%, mature on April 11, 2020, and may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 25% discount to the lowest bid or trading price of the Company’s common stock during the ten (10) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due. On April 15, 2019, the Company issued a convertible note with a face value of $357,500. The note included $32,500 fees for net proceeds of $325,000. The note has an interest rate of 10%, matures on December 31, 2019, and may be converted into common stock of the Company by the holder at any time, subject to a 9.99% beneficial ownership limitation, at a fixed conversion price per share of $0.20. Upon an event of default, 140% of the outstanding principal and any interest due amount shall be immediately due and the conversion price resets to a 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. On May 7, 2019, the Company entered into a securities purchase agreement for the sale of a $103,000 convertible note. The note included $3,000 fees for net proceeds of $100,000. The note has an interest rate of 10% and a default interest rate of 22%, matures on February 28, 2020 and may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the lowest bid or trading price of the Company’s common stock during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due. On May 7, 2018, the Company prepaid the balance on a convertible note payable dated November 12, 2018 with a face value of $103,000, plus interest accrued thereon, for a one-time cash payment of $134,888.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about collection of accounts receivable, the valuation and recognition of stock-based compensation expense, valuation allowance for deferred tax assets, borrowing rate consideration for ROU lease assets including related lease liability and useful life of fixed assets.
Adopted Accounting Pronouncements	Adopted Accounting Pronouncements Effective January 1, 2019, the Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (“ASU 2016-02”) using the required modified retrospective approach. ASU 2016-02 requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. See discussion below under the caption “Leases” in this Note 2 and in Note 7 for more detail on the Company’s accounting policy with respect to lease accounting. Effective January 1, 2019, the Company adopted ASU 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees and supersedes the guidance in Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. The .
Patient Service Revenue	Patient Service Revenue Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected charges. The Company believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Company does not believe it is required to provide additional goods or services to the patient. The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. The Company determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows: ● Medicare: ● Medicaid: ● Other: Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims. Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations. The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change.
Cash and Cash Equivalents	Cash and Cash Equivalents For financial statement purposes, the Company considers all highly-liquid investments with original maturities of three months or less to be cash and cash equivalents.
Accounts Receivable	Accounts Receivable Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 47% of total billings. Trade accounts receivable are recorded at this net amount. As of March 31, 2019 and December 31, 2018, the Company’s gross accounts receivable were $227,943 and $244,956, respectively, and net accounts receivable were $106,905 and $114,884, respectively, based upon net reporting of accounts receivable. As of March 31, 2019 and December 31, 2018, the Company’s allowance of doubtful accounts was $13,972 and $13,972, respectively.
Leases	Leases Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as right-of-use (“ROU”) assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company’s condensed consolidated balance sheets. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Adoption of ASU 2016-02 had an impact of $355,447 and $356,517 million on the Company’s assets and liabilities, respectively, and had no material impact on cash provided by or used in operating, investing or financing activities on the Company’s unaudited condensed consolidated statements of cash flows.
Concentrations of Credit Risk	Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. There was no impairment as of March 31, 2019 and December 31, 2018.
Convertible Notes	Convertible Notes Convertible notes are regarded as compound instruments, consisting of a liability component and an equity component. The component parts of compound instruments are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangement. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortized cost basis until extinguished upon conversion or at the instrument’s maturity date. The equity component is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized as additional paid-in capital and included in equity, net of income tax effects, and is not subsequently remeasured. After initial measurement, they are carried at amortized cost using the effective interest method. Convertible notes for which the maturity date has been extended and that qualify for debt extinguishment treatment are recorded at fair value on the extinguishment date and then revalue at the end of each reporting period, with the change recorded to the statement of operations under “Change in Fair Value of Debt.”
Derivative Financial Instruments	Derivative Financial Instruments The Company reviews the terms of convertible debt, equity instruments and other financing arrangements to determine whether there are embedded derivative instruments, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Also, in connection with the issuance of financing instruments, the Company may issue freestanding options or warrants that may, depending on their terms, be accounted for as derivative instrument liabilities, rather than as equity. Derivative financial instruments are initially measured at their fair value. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. To the extent that the initial fair values of the freestanding and/or bifurcated derivative instrument liabilities exceed the total proceeds received, an immediate charge to income is recognized, in order to initially record the derivative instrument liabilities at their fair value. The discount from the face value of convertible debt instruments resulting from allocating some or all of the proceeds to the derivative instruments is amortized over the life of the instrument through periodic charges to income. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. If reclassification is required, the fair value of the derivative instrument, as of the determination date, is reclassified. Any previous charges or credits to income for changes in the fair value of the derivative instrument are not reversed. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date. The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks.
Fair Value of Assets and Liabilities	Fair Value of Assets and Liabilities Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs: ● Level 1 – ● Level 2 ● Level 3 The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation under ASC 718 “Compensation – Stock Compensation” using the fair value based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges it equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods.
Income Taxes	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No Income Tax has been provided for the three months ended March 31, 2019, since the Company has sustained a loss for the period. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards (including the three months ended March 31, 2019) and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable.
Recurring Fair Value Measurements	Recurring Fair Value Measurements The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, short-term borrowings, accounts payable, accrued liabilities, and derivative financial instruments approximated their fair value.
Net Income (Loss) per Share	Net Loss per Share Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three months ended March 31, 2019 and 2018, the Company reported a net loss and excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of March 31, 2019 and December 31, 2018, potentially dilutive securities were comprised of (i) 45,058,874 and 46,161,463 warrants outstanding, respectively, (ii) 3,549,250 and 3,707,996 stock options outstanding, respectively, (iii) 10,346,866 and 15,517,111 shares issuable upon conversion of convertible notes, respectively, and (iv) 463,750 and 565,000 unissued shares subject to future vesting requirements granted pursuant to the Company's Employee Incentive Plan.
Common stock awards	Common stock awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of comprehensive loss in the same manner and charged to the same account as if such settlements had been made in cash.
Warrants	Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 11, Shareholders’ Deficit
Business Segments	Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has two operating segments: NWC (multi-specialty medical group including OB/GYN and General Practice) and HLYK (develops and markets the “HealthLynked Network,” an online personal medical information and record archive system).

Property, Plant, and Equipment

Property, Plant, and Equipment (Tables)	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of property, plant and equipment	March 31, December 31, 2019 2018 Capital Lease equipment $ 251,752 $ 343,492 Telephone equipment 12,308 12,308 Furniture, Transport and Office equipment 443,271 438,970 Total Property, plant and equipment 707,331 794,770 Less: accumulated depreciation (683,494 ) (752,173 ) Property, plant and equipment, net $ 23,837 $ 42,597

Notes Payable and Other Amoun_2

Notes Payable and Other Amounts Due to Related Party (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Payable and Other Amounts Due to Related Party [Abstract]
Schedule of amounts due to related parties	March 31, December 31, 2019 2018 Due to related party: Deferred compensation, Dr. Michael Dent $ 300,600 $ 300,600 Accrued interest payable to Dr. Michael Dent 145,676 129,117 Total due to related party 446,276 429,717 Notes payable to related party: Notes payable to Dr. Michael Dent, current portion 678,329 553,550
Schedule of notes payable	Interest March 31, December 31, Inception Date Maturity Date Borrower Rate 2019 2018 January 12, 2017 January 13, 2019 HLYK 10 % $ 41,750 * $ 40,560 * January 18, 2017 January 19, 2019 HLYK 10 % 23,827 * 23,165 * January 24, 2017 January 15, 2019 HLYK 10 % 59,491 * 57,839 * February 9, 2017 February 10, 2019 HLYK 10 % 35,574 * 34,586 * April 20, 2017 April 21, 2019 HLYK 10 % 11,681 * 11,357 * June 15, 2017 June 16, 2019 HLYK 10 % 37,506 * 36,464 * August 17, 2017 August 18, 2018 HLYK 10 % 20,000 20,000 August 24, 2017 August 25, 2018 HLYK 10 % 37,500 37,500 September 7, 2017 September 8, 2018 HLYK 10 % 35,000 35,000 September 21, 2017 September 22, 2018 HLYK 10 % 26,500 26,500 September 29, 2017 September 30, 2018 HLYK 10 % 12,000 12,000 December 21, 2017 December 22, 2018 HLYK 10 % 14,000 14,000 January 8, 2018 January 9, 2019 HLYK 10 % 75,000 75,000 January 11, 2018 January 12, 2019 HLYK 10 % 9,000 9,000 January 26, 2018 January 27, 2019 HLYK 10 % 17,450 17,450 January 3, 2014 December 31, 2018 NWC 10 % 222,050 222,050 $ 678,329 $ 672,471 * - Denotes that note payable is carried at fair value

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Schedule of maturities of operating lease liabilities	Operating Capital Total Leases Leases Commitments 2019 (April through December) $ 206,098 $ 13,761 $ 219,859 2020 162,055 4,587 166,642 2021 --- --- --- 2022 --- --- --- 2023 --- --- --- Total lease payments 368,153 18,348 386,501 Less interest (28,957 ) (1,027 ) (29,984 ) Present value of lease liabilities $ 339,196 $ 17,321 $ 356,517

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2019
Short-term Debt [Line Items]
Schedule of notes payable	March 31, December 31, 2019 2018 $550k Note - July 2016 $ 611,651 * $ 594,813 $50k Note - July 2016 62,019 * 60,312 $111k Note - May 2017 128,734 * 125,190 $171.5k Note - October 2017 --- 186,472 $103k Note I - October 2018 103,000 103,000 $103k Note II - November 2018 103,000 103,000 $153k Note - November 2018 153,000 153,000 $103k Note III - December 2018 103,000 103,000 $78k Note I - January 2019 78,000 --- $78k Note II - January 2019 78,000 --- 1,420,404 1,428,787 Less: unamortized discount (363,089 ) (386,473 ) Convertible notes payable, net of original issue discount and debt discount 1,057,315 1,042,314 * - Denotes that convertible note payable is carried at fair value
Schedule of amortization expense and interest expense	Amortization of Debt Discount Interest Expanse Three Months Ended Three Months Ended 2019 2018 2019 2018 $550k Note - July 2016 $ --- $ --- $ 8,137 $ 8,137 $50k Note - July 2016 --- --- 1,233 1,233 $111k Note - May 2017 --- 11,011 4,078 4,078 $53k Note - July 2017 --- 1,520 --- 116 $35k Note - September 2017 --- 7,972 --- 614 $55k Note - September 2017 --- 10,849 --- 1,085 $53k Note II - October 2017 --- 17,036 --- 1,307 $171.5k Note - October 2017 --- 42,404 1,785 4,229 $57.8k Note - January 2018 --- 13,923 --- 1,392 $112.8k Note - February 2018 --- 17,608 --- 1,761 $83k Note - February 2018 --- 10,460 --- 1,046 $105k Note - March 2018 --- 7,479 --- 748 $103k Note I - October 2018 32,526 --- 2,540 --- $103k Note II - November 2018 31,856 --- 2,540 --- $153k Note - November 2018 50,440 --- 3,773 --- $103k Note III - December 2018 25,397 --- 2,540 --- $78k Note I - January 2019 21,714 --- 1,624 --- $78k Note II - January 2019 17,451 --- 1,410 --- $ 179,384 $ 140,262 $ 29,660 $ 25,746
Schedule of unamortized debt discount on outstanding convertible notes payable	Unamortized Discount as of March 31, December 31, 2019 2018 $103k Note I - October 2018 $ 43,730 $ 76,256 $103k Note II - November 2018 53,801 85,656 $153k Note - November 2018 79,022 129,462 $103k Note III - December 2018 69,701 95,099 $78k Note I - January 2019 56,286 --- $78k Note II - January 2019 60,549 --- $ 363,089 $ 386,473
Schedule of convertible notes payable	Change in Fair Value of Debt Fair Value of Debt as of Three Months Ended March 31, March 31, December 31, 2019 2018 2019 2018 $550k Note - July 2016 $ 16,838 $ 46,298 $ 611,651 $ 594,813 $50k Note - July 2016 1,707 8,199 62,019 60,312 $111k Note - May 2017 3,544 8,815 128,734 125,190 $171.5k Note - October 2017 1,781 --- --- 186,472 $ 23,870 $ 63,312 $ 802,404 $ 966,787
Convertible Notes Payable ($35,000) - September 2017
Short-term Debt [Line Items]
Schedule of debt extinguishment	Cash repayment $ 49,502 Less face value of convertible note payable retired (35,000 ) Less carrying value of derivative financial instruments arising from ECF (37,269 ) Less accrued interest (1,716 ) Plus carrying value of discount at extinguishment 12,705 Gain on extinguishment of debt $ (11,778 )
Convertible Notes Payable ($55,000) - September 2017
Short-term Debt [Line Items]
Schedule of debt extinguishment	Cash repayment $ 85,258 Less face value of convertible note payable retired (55,000 ) Less carrying value of derivative financial instruments arising from ECF (69,687 ) Less accrued interest (2,759 ) Plus carrying value of discount at extinguishment 27,425 Gain on extinguishment of debt $ (14,763 )
Convertible Notes Payable ($53,000) - July 2017 [Member]
Short-term Debt [Line Items]
Schedule of debt extinguishment	Cash repayment $ 74,922 Less face value of convertible note payable retired (53,000 ) Less carrying value of derivative financial instruments arising from ECF (53,893 ) Less accrued interest (2,644 ) Plus carrying value of discount at extinguishment 18,427 Gain on extinguishment of debt $ (16,188 )
Convertible Notes Payable ($78,000) – January 2019 [Member]
Short-term Debt [Line Items]
Schedule of convertible notes payable	Embedded conversion feature $ 78,088 Original issue discount and fees 3,000 Fair value of shares recorded to equity 4,676 Financing cost (7,764 ) Convertible note --- Gross proceeds $ 78,000
Convertible Notes Payable ($78,000) – January 2019 one [Member]
Short-term Debt [Line Items]
Schedule of convertible notes payable	Embedded conversion feature $ 101,139 Original issue discount and fees 3,000 Financing cost (26,139 ) Convertible note --- Gross proceeds $ 78,000

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of derivative financial instruments	Change in Fair Value Inception of Fair Value Conversion Fair Value as of Derivative of Derivative of Derivative as of December 31, Financial Financial Financial March 31, 2018 Instruments Instruments Instruments 2019 $171.5k Note - October 2017 $ 229,902 $ --- $ (22,720 ) $ (207,182 ) $ --- $103k Note I - October 2018 131,617 --- (33,857 ) --- 97,760 $103k Note II - November 2018 135,845 --- (32,378 ) --- 103,467 $153k Note - November 2018 157,426 --- (45,408 ) --- 112,018 $103k Note III - December 2018 145,650 --- (28,544 ) --- 117,106 $78k Note I - January 2019 --- 78,088 (14,573 ) --- 63,515 $78k Note II - January 2019 --- 101,142 (14,153 ) --- 86,989 $ 800,440 $ 179,230 $ (191,633 ) $ (207,182 ) $ 580,855 Change in Fair Value Inception of Fair Value Write off Fair Value as of Derivative of Derivative Derivative as of December 31, Financial Financial Financial March 31, 2017 Instruments Instruments Instruments 2018 (audited) $53k Note - July 2017 $ 48,876 $ --- $ 5,017 $ (53,893 ) $ --- $35k Note - September 2017 36,161 --- 1,108 (37,269 ) --- $55k Note - September 2017 64,656 --- 5,032 (69,688 ) --- $53k Note #2 - October 2017 58,216 --- 617 --- 58,833 $171.5k Note - October 2017 190,580 --- 11,979 --- 202,559 $57.8k Note - January 2018 --- 82,653 (2,905 ) --- 79,748 $112.8k Note - February 2018 --- 161,527 (2,371 ) --- 159,156 $83k Note - February 2018 --- 119,512 (1,525 ) --- 117,987 $105k Note - March 2018 --- 153,371 (2,331 ) --- 151,040 $ 398,489 $ 517,063 $ 14,621 $ (160,850 ) $ 769,323

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2019
Option Indexed to Issuer's Equity [Line Items]
Schedule of stock warrants	2019 2018 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 46,161,463 $ 0.18 20,526,387 $ 0.23 Granted during the period 996,667 $ 0.42 9,156,403 $ 0.09 Exercised during the period (2,099,256 ) $ 0.00 --- $ --- Terminated during the period --- $ --- --- $ --- Outstanding at end of the period 45,058,874 $ 0.19 29,682,790 $ 0.19 Exercisable at end of the period 45,058,874 $ 0.19 29,682,790 $ 0.19 Weighted average remaining life 3.5 years 4.9 years
Schedule of stock options outstanding	2019 2018 Weighted Weighted Average Average Exercise Exercise Number Price Number Price Outstanding at beginning of the period 3,707,996 $ 0.18 2,349,996 $ 0.12 Granted during the period 591,250 $ 0.26 --- $ --- Exercised during the period (154,166 ) $ 0.20 --- $ --- Forfeited during the period (595,830 ) $ 0.20 --- $ --- Outstanding at end of the period 3,549,250 $ 0.19 2,349,996 $ 0.12 Options exercisable at period-end 1,261,000 637,500 Weighted average remaining life (in years) 8.2 8.4 Weighted average grant date fair value of options granted during the period $ 0.21 $ --- Options available for grant at period-end 10,154,118 11,654,934
Employee Stock Option [Member]
Option Indexed to Issuer's Equity [Line Items]
Schedule of stock warrants outstanding	Options Outstanding Options Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ --- to 0.10 1,733,000 6.9 $ 0.08 1,183,000 0.08 $ 0.11 to 0.31 1,816,250 9.5 $ 0.29 78,000 0.31 $ 0.08 to 0.31 3,549,250 8.2 $ 0.19 1,261,000 $ 0.10
Schedule of non-vested shares issued	2019 2018 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Nonvested at beginning of period 2,332,413 $ 0.13 1,774,996 $ 0.03 Granted 591,250 $ 0.21 --- $ --- Vested (39,583 ) $ 0.03 (62,500 ) $ 0.03 Forfeited (595,830 ) $ 0.02 --- $ --- Nonvested at end of period 2,288,250 $ 0.18 1,712,496 $ 0.03
Schedule of stock options outstanding	Options Outstanding Options Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ --- to 0.10 1,733,000 6.9 $ 0.08 1,183,000 0.08 $ 0.11 to 0.31 1,816,250 9.5 $ 0.29 78,000 0.31 $ 0.08 to 0.31 3,549,250 8.2 $ 0.19 1,261,000 $ 0.10
Employee Equity Incentive Plan [Member]
Option Indexed to Issuer's Equity [Line Items]
Schedule of shares issued and outstanding under the EIP outstanding	2019 2018 Weighted Weighted Average Average Grant Date Grant Date Shares Fair Value Shares Fair Value Nonvested at beginning of period 540,000 $ 0.16 628,750 $ 0.05 Granted --- $ --- --- $ --- Vested (76,250 ) $ 0.04 (188,750 ) $ 0.04 Forfeited --- $ --- --- $ --- Nonvested at end of period 463,750 $ 0.18 440,000 $ 0.05
Warrant [Member]
Option Indexed to Issuer's Equity [Line Items]
Schedule of stock warrants outstanding	Warrants Outstanding Warrants Exercisable Weighted- Average Weighted- Weighted- Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life (years) Price Exercisable Price $ 0.0001 to 0.09 18,157,768 3.6 $ 0.06 18,157,768 $ 0.06 $ 0.10 to 0.24 14,520,441 3.8 $ 0.19 14,520,441 $ 0.19 $ 0.25 to 0.49 8,440,665 3.3 $ 0.29 8,440,665 $ 0.29 $ 0.50 to 1.00 3,940,000 2.9 $ 0.64 3,940,000 $ 0.64 $ 0.05 to 1.00 45,058,874 3.5 $ 0.20 45,058,874 $ 0.20

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of maturities operating lease liabilities	Operating Capital Total Leases Leases Commitments 2019 (April through December) $ 206,098 $ 13,761 $ 219,859 2020 162,055 4,587 166,642 2021 --- --- --- 2022 --- --- --- 2023 --- --- --- Total lease payments 368,153 18,348 386,501 Less interest (28,957 ) (1,027 ) (29,984 ) Present value of lease liabilities $ 339,196 $ 17,321 $ 356,517

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Schedule of segment information	Three Months Ended March 31, 2019 Three Months Ended March 31, 2018 NWC HLYK Total NWC HLYK Total Revenue Patient service revenue, net $ 464,990 $ --- $ 464,990 $ 645,639 $ --- $ 645,639 Operating Expenses Salaries and benefits 350,238 178,987 529,225 403,055 157,801 560,856 General and administrative 242,600 514,756 757,356 225,652 349,176 574,828 Depreciation and amortization 1,060 595 1,655 5,574 455 6,029 Total Operating Expenses 593,898 694,338 1,288,236 634,281 507,432 1,141,713 Loss from operations $ (128,908 ) $ (694,338 ) $ (823,246 ) $ 11,358 $ (507,432 ) $ (496,074 ) Other Segment Information Interest expense $ 5,828 $ 40,494 $ 46,322 $ 5,697 $ 34,650 $ 40,347 Loss on extinguishment of debt $ --- $ 139,798 $ 139,798 $ --- $ 325,223 $ 325,223 Financing cost $ --- $ 33,903 $ 33,903 $ --- $ 192,062 $ 192,062 Amortization of original issue and debt discounts on convertible notes $ --- $ 179,384 $ 179,384 $ --- $ 154,835 $ 154,835 Change in fair value of debt $ --- $ 29,697 $ 29,697 $ --- $ 57,946 $ 57,946 Change in fair value of derivative financial instruments $ --- $ (191,633 ) $ (191,633 ) $ --- $ 14,621 $ 14,621 March 31, 2019 December 31, 2018 Identifiable assets $ 520,535 $ 565,751 $ 1,086,286 $ 184,912 $ 242,451 $ 427,363

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Schedule of fair value measurements	As of March 31, 2019 Total Level 1 Level 2 Level 3 Fair Value Convertible notes payable $ --- $ --- $ 802,404 $ 802,404 Notes payable to related party --- --- 209,829 209,829 Derivative financial instruments --- --- 580,855 580,855 Total $ --- $ --- $ 1,593,088 $ 1,593,088 As of December 31, 2018 Total Level 1 Level 2 Level 3 Fair Value Convertible notes payable $ --- $ --- $ 780,315 $ 780,315 Notes payable to related party --- --- 203,971 203,971 Derivative financial instruments --- --- 800,440 800,440 Total $ --- $ --- $ 1,784,726 $ 1,784,726
Level 3 financial instruments [Member]
Schedule of fair value measurements	Three Months Ended 2019 2018 Convertible notes payable $ (23,869 ) $ (54,497 ) Notes payable to related party (5,828 ) (3,449 ) Derivative financial instruments 191,633 (14,621 ) Total $ 161,936 $ (72,567 )

Business and Business Present_2

Business and Business Presentation (Details) - shares	Sep. 05, 2014	Feb. 05, 2018	Sep. 03, 2014
Business and Business Presentation (Textual)
Total authorized shares			250,000,000
Common shares			230,000,000
Preferred shares			20,000,000
Increase authorized shares of common stock		500,000,000
Share Exchange Agreement [Member]
Business and Business Presentation (Textual)
Equity method investment ownership percentage	100.00%
Stock issued during period shares acquisitions	50,000,000

Significant Accounting Polici_3

Significant Accounting Policies (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Significant Accounting Policies (Textual)
Percentage of customers accounts receivable billings	45.00%
Accounts receivable gross	$ 227,943	$ 244,956
Accounts receivable net	$ 106,905	114,884
Concentration risk, percentage	10.00%
Allowance of doubtful accounts	$ 13,972	$ 13,972
Total lease assets	355,447
Total lease liabilities	$ 356,517
Convertible Notes [Member]
Significant Accounting Policies (Textual)
Anti-dilutive securities	10,346,866	15,517,111
Minimum [Member]
Significant Accounting Policies (Textual)
Estimated useful lives	5 years
Maximum [Member]
Significant Accounting Policies (Textual)
Estimated useful lives	7 years
Stock Options [Member]
Significant Accounting Policies (Textual)
Anti-dilutive securities	3,549,250	3,707,996
Warrant [Member]
Significant Accounting Policies (Textual)
Anti-dilutive securities	45,058,874	46,161,463
Unissued [Member]
Significant Accounting Policies (Textual)
Anti-dilutive securities	463,750	565,000

Going Concern Matters and Liq_2

Going Concern Matters and Liquidity (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Jul. 31, 2016
Going Concern Matters and Liquidity (Textual)
Working capital deficit	$ 2,778,539
Accumulated deficit	(11,561,772)		$ (10,501,055)
Net loss	(1,060,717)	$ (1,281,108)
Net cash used by operating activities	(600,393)	(424,154)
Net cash used in investing activities	(4,302)	(201)
Net cash provided by financing activities	983,226	403,659
Proceeds from sale of common stock	833,226	251,568
Net proceeds from issuance of convertible notes	150,000	325,000
Proceeds from related party loans		$ 101,450
HLYK [Member]
Going Concern Matters and Liquidity (Textual)
Proceeds from sale of common stock	$ 493,226
Sale of common stock shares	2,128,644
Investor agreed to purchase of common stock				$ 3,000,000

Deferred Offering Costs and P_2

Deferred Offering Costs and Prepaid Expenses (Details)	Dec. 06, 2018USD ($)$ / sharesshares	Jun. 07, 2017USD ($)$ / sharesshares	Mar. 22, 2017USD ($)shares	Jul. 07, 2016USD ($)Days$ / shares	Mar. 31, 2019USD ($)$ / shares	Mar. 31, 2018USD ($)	Dec. 31, 2018$ / shares
Deferred Offering Costs and Prepaid Expenses (Textual)
Common stock par value, per share | $ / shares					$ 0.0001		$ 0.0001
Fair of warrants issued for professional service					$ 14,743
General and administrative					757,356	574,828
Warrants [Member]
Deferred Offering Costs and Prepaid Expenses (Textual)
General and administrative					25,611	0
Two Advisor [Member]
Deferred Offering Costs and Prepaid Expenses (Textual)
Fair of warrants issued for professional service	$ 35,462
Risk-free interest rate	2.76%
Expected life (in years)	3 years
Expected volatility rate	285.22%
Expected dividend yield	0.00%
Warrants to purchase of common stock | shares	240,000
Warrants to purchase, per share | $ / shares	$ 0.20
Advisor [Member]
Deferred Offering Costs and Prepaid Expenses (Textual)
Warrants to purchase of common stock | shares		200,000
Warrants to purchase, per share | $ / shares		$ 0.25
Advisor One [Member]
Deferred Offering Costs and Prepaid Expenses (Textual)
Warrants to purchase of common stock | shares		100,000
Warrants to purchase, per share | $ / shares		$ 0.50
Advisor Two [Member]
Deferred Offering Costs and Prepaid Expenses (Textual)
Warrants to purchase of common stock | shares		50,000
Warrants to purchase, per share | $ / shares		$ 1
Investment Agreement [Member]
Deferred Offering Costs and Prepaid Expenses (Textual)
General and administrative					$ 12,802	$ 12,802
Investment Agreement [Member] | Accredited Investor [Member]
Deferred Offering Costs and Prepaid Expenses (Textual)
Amount invested to purchase of common stock				$ 3,000,000
Common stock par value, per share | $ / shares				$ 0.0001
Purchase price of shares, percentage				80.00%
Common stock, trading days | Days				5
Payments to purchase of common stock				$ 50,000
Weighted average purchase price				$ 50,000
Warrants expiration, term				5 years
Warrants exercise price, percentage				130.00%
Amended Investment Agreement [Member] | Investor [Member]
Deferred Offering Costs and Prepaid Expenses (Textual)
Warrants exercise prices, description			(i) 4,000,000 shares at $0.25 per share; (ii) 2,000,000 shares at $0.50 per share; and (iii) 1,000,000 shares at $1.00 per share.
Fair of warrants issued for professional service		$ 96,990	$ 56,635
Risk-free interest rate		1.74%	1.95%
Expected life (in years)		5 years	5 years
Expected volatility rate		40.00%	40.00%
Expected dividend yield		0.00%	0.00%
Granting the investor warrants to tender			$ 50,000
Warrants to purchase of common stock | shares			7,000,000

Property, Plant, and Equipmen_2

Property, Plant, and Equipment (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	$ 707,331	$ 794,770
Less: accumulated depreciation	(683,494)	(752,173)
Property, plant and equipment, net	23,837	42,597
Telephone equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	12,308	12,308
Furniture, Transport and Office equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	443,271	438,970
Capital Lease equipment [Member]
Property, Plant and Equipment [Line Items]
Total Property, plant and equipment	$ 251,752	$ 343,492

Property, Plant, and Equipmen_3

Property, Plant, and Equipment (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Property, Plant, and Equipment (Textual)
Depreciation expense	$ 1,655	$ 6,029

Notes Payable and Other Amoun_3

Notes Payable and Other Amounts Due to Related Party (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Due to related party:
Total due to related party	$ 446,276	$ 429,717
Notes payable to related party:
Notes payable to Dr. Michael Dent, current portion	678,329	672,471
Deferred compensation, Dr. Michael Dent [Member]
Due to related party:
Total due to related party	300,600	300,600
Accrued interest payable to Dr. Michael Dent [Member]
Due to related party:
Total due to related party	145,676	129,117
Notes Payable To Dr Michael Dent Current Portion [Member]
Notes payable to related party:
Notes payable to Dr. Michael Dent, current portion	$ 678,329	$ 553,550

Notes Payable and Other Amoun_4

Notes Payable and Other Amounts Due to Related Party (Details 1) - USD ($)		3 Months Ended	12 Months Ended
		Mar. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Issuance of unsecured promissory notes, Amount		$ 678,329	$ 672,471
Dr. Michael Dent [Member] | Unsecured Note Payable [Member]
Related Party Transaction [Line Items]
Inception Date		Jan. 12, 2017
Maturity Date		Jan. 13, 2019
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount	[1]	$ 41,750	40,560
Dr. Michael Dent [Member] | Unsecured Note Payable one [Member]
Related Party Transaction [Line Items]
Inception Date		Jan. 18, 2017
Maturity Date		Jan. 19, 2019
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount	[1]	$ 23,827	23,165
Dr. Michael Dent [Member] | Unsecured Note Payable two [Member]
Related Party Transaction [Line Items]
Inception Date		Jan. 24, 2017
Maturity Date		Jan. 15, 2019
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount	[1]	$ 59,491	57,839
Dr. Michael Dent [Member] | Unsecured Note Payable three [Member]
Related Party Transaction [Line Items]
Inception Date		Feb. 9, 2017
Maturity Date		Feb. 10, 2019
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount	[1]	$ 35,574	34,586
Dr. Michael Dent [Member] | Unsecured Note Payable four [Member]
Related Party Transaction [Line Items]
Inception Date		Apr. 20, 2017
Maturity Date		Apr. 21, 2019
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount	[1]	$ 11,681	11,357
Dr. Michael Dent [Member] | Unsecured Note Payable five [Member]
Related Party Transaction [Line Items]
Inception Date		Jun. 15, 2017
Maturity Date		Jun. 16, 2019
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount	[1]	$ 37,506	36,464
Dr. Michael Dent [Member] | Unsecured Note Payable six [Member]
Related Party Transaction [Line Items]
Inception Date		Aug. 17, 2017
Maturity Date		Aug. 18, 2018
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount		$ 20,000	20,000
Dr. Michael Dent [Member] | Unsecured Note Payable seven [Member]
Related Party Transaction [Line Items]
Inception Date		Aug. 24, 2017
Maturity Date		Aug. 25, 2018
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount		$ 37,500	37,500
Dr. Michael Dent [Member] | Unsecured Note Payable eight [Member]
Related Party Transaction [Line Items]
Inception Date		Sep. 7, 2017
Maturity Date		Sep. 8, 2018
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount		$ 35,000	35,000
Dr. Michael Dent [Member] | Unsecured Note Payable nine [Member]
Related Party Transaction [Line Items]
Inception Date		Sep. 21, 2017
Maturity Date		Sep. 22, 2018
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount		$ 26,500	26,500
Dr. Michael Dent [Member] | Unsecured Note Payable ten [Member]
Related Party Transaction [Line Items]
Inception Date		Sep. 29, 2017
Maturity Date		Sep. 30, 2018
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount		$ 12,000	12,000
Dr. Michael Dent [Member] | Unsecured Note Payable eleven [Member]
Related Party Transaction [Line Items]
Inception Date		Dec. 21, 2017
Maturity Date		Dec. 22, 2018
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount		$ 14,000	14,000
Dr. Michael Dent [Member] | Unsecured Note Payable twelve [Member]
Related Party Transaction [Line Items]
Inception Date		Jan. 8, 2018
Maturity Date		Jan. 9, 2019
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount		$ 75,000	75,000
Dr. Michael Dent [Member] | Unsecured Note Payable thirteen [Member]
Related Party Transaction [Line Items]
Inception Date		Jan. 11, 2018
Maturity Date		Jan. 12, 2019
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount		$ 9,000	9,000
Dr. Michael Dent [Member] | Unsecured Note Payable fourteen [Member]
Related Party Transaction [Line Items]
Inception Date		Jan. 26, 2018
Maturity Date		Jan. 27, 2019
Borrower		HLYK
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount		$ 17,450	17,450
Dr. Michael Dent [Member] | Unsecured Note Payable fifteen [Member]
Related Party Transaction [Line Items]
Inception Date		Jan. 3, 2014
Maturity Date		Dec. 31, 2018
Borrower		NWC
Interest Rate		10.00%
Issuance of unsecured promissory notes, Amount		$ 222,050	$ 222,050
[1]	Denotes that note payable is carried at fair value

Notes Payable and Other Amoun_5

Notes Payable and Other Amounts Due to Related Party (Details Textual) - USD ($)	Jul. 18, 2018	Jul. 03, 2018	Mar. 28, 2018	Feb. 12, 2018	Dec. 31, 2014	Aug. 31, 2014	Dec. 31, 2013	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Notes Payable and Other Amounts Due to Related Party (Textual)
Issuance of unsecured promissory notes								$ 678,329		$ 672,471
Amount payable								446,276		429,717
Maturity date, description	Until December 31, 2019.
General and administrative expense								757,356	$ 574,828
Fair value of warrants								14,743
Reissued debt amount								(29,697)	(57,946)
Loss on extinguishment of debt								(139,798)	(325,223)
Change in fair value of debt								5,828	3,449
750k DMD Note [Member]
Notes Payable and Other Amounts Due to Related Party (Textual)
Interest accrued								72,687		66,859
Dr. Michael Dent [Member]
Notes Payable and Other Amounts Due to Related Party (Textual)
Maturity date, description	In connection with a $2,000,000 private placement by a third party investor, Dr. Dent agreed to extend the maturity date on all of the above notes until December 31, 2019.		The maturity dates of promissory notes with an aggregate face value of $177,500, which were originally scheduled to mature before September 30, 2018, by one year from the original maturity date.
Warrant to purchase of common stock, shares				6,678,462
Description of warrants				(i) extend the maturity dates of up to $439,450 loaned by Dr. Dent to the Company in 2017 and 2018 in the form of unsecured promissory notes, including $75,000 loaned from Dr. Dent to the Company in January 2018 to allow the Company to retire an existing convertible promissory note payable to Power-up Lending Group Ltd. before such convertible promissory note became eligible for conversion, and (ii) provide continued loans to the Company. The warrant is immediately exercisable at an exercise price of $0.065 per share, subject to adjustment, and expires five years after the date of issuance.
Fair value of warrants				$ 337,466
Risk-free interest rate				2.56%
Expected life (in years)				5 years
Expected volatility rate				268.90%
Expected dividend yield				0.00%
Reissued debt amount			$ 11,472
Dr. Michael Dent [Member] | NWC [Member]
Notes Payable and Other Amounts Due to Related Party (Textual)
Issuance of unsecured promissory notes						$ 175,000
Interest rate						0.00%
Notes payable, maturity date					Dec. 31, 2017
Increased on unsecured note payable					$ 750,000		$ 500,000
MedOffice Direct (MOD) [Member]
Notes Payable and Other Amounts Due to Related Party (Textual)
Interest rate		8.00%
Rent expense related to the marketing agreement								0	6,120
Maturity date, description											The Company and its employees for the period from January 1, 2017 through July 31, 2018.
Semi annual fees											$ 25,000
General and administrative expense								0	$ 12,500
Dr Dent [Member]
Notes Payable and Other Amounts Due to Related Party (Textual)
Interest accrued								$ 73,020		$ 62,258

Leases (Details)

Leases (Details)	Mar. 31, 2019USD ($)
Lease assets	$ 355,447
Lease liabilities
Lease liabilities (short term)	266,130
Lease liabilities (long term)	90,387
Total lease liabilities	356,517
Operating Leases [Member]
Lease assets	338,126
Lease liabilities
Lease liabilities (short term)	248,809
Lease liabilities (long term)	90,387
Total lease liabilities	339,196
Financing Leases [Member]
Lease assets	17,321
Lease liabilities
Lease liabilities (short term)	17,321
Lease liabilities (long term)
Total lease liabilities	$ 17,321

Leases (Details 1)

Leases (Details 1)	Mar. 31, 2019USD ($)
2019 (April through December)	$ 219,859
2020	166,642
2021
2022
2023
Total lease payments	386,501
Less interest	(29,984)
Present value of lease liabilities	356,517
Operating Leases [Member]
2019 (April through December)	206,098
2020	162,055
2021
2022
2023
Total lease payments	368,153
Less interest	(28,957)
Present value of lease liabilities	339,196
Capital Leases [Member]
2019 (April through December)	13,761
2020	4,587
2021
2022
2023
Total lease payments	18,348
Less interest	(1,027)
Present value of lease liabilities	$ 17,321

Leases (Details Textual)

Leases (Details Textual)	3 Months Ended
	Mar. 31, 2019USD ($)
Leases (Textual)
Operating leases, description	The Company has two operating leases for office space and equipment that expire in July 2020. The Company's weighted-average remaining lease term relating to its operating leases is 1.3 years, with a weighted-average discount rate of 11.71%. The Company is also lessee in a capital equipment finance lease for medical equipment entered into in March 2015 and expiring in March 2020. The Company's weighted-average remaining lease term relating to its financing lease is 1.0 years, with a weighted-average discount rate of 9.38%.
Incurred lease expense	$ 73,415
Related to operating leases	68,828
Related to financing leases	$ 4,587

Notes Payable (Details)

Notes Payable (Details) - USD ($)	1 Months Ended	3 Months Ended
	Dec. 20, 2017	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Notes Payable (Textual)
Discount against the note payable		$ 363,089		$ 386,473
Power Up Lending Group, Ltd. [Member] | Merchant Cash Advance Factoring Agreement [Member]
Notes Payable (Textual)
Advance received for factoring agreement	$ 75,000
Description of payables in factoring agreement	The Company is required to repay the advance, which acts like an ordinary note payable, at the rate of $4,048 per week until the balance of $102,000, which was scheduled for June 2018.
Discount against the note payable	$ 28,500
Recognized to amortize the remaining discount		0	$ 14,574
Note payable	$ 102,000
Repayments		$ 0	$ 52,619

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2019		Dec. 31, 2018
Debt Instrument [Line Items]
Total	$ 1,420,404		$ 1,428,787
Less: unamortized discount	(363,089)		(386,473)
Convertible notes payable, net of original issue discount and debt discount	1,057,315		1,042,314
$550k Note - July 2016 [Member]
Debt Instrument [Line Items]
Total	611,651	[1]	594,813
$50k Note - July 2016 [Member]
Debt Instrument [Line Items]
Total	62,019	[1]	60,312
$111k Note - May 2017 [Member]
Debt Instrument [Line Items]
Total	128,734	[1]	125,190
$171.5k Note - October 2017 [Member]
Debt Instrument [Line Items]
Total			186,472
$103k Note I - October 2018 [Member]
Debt Instrument [Line Items]
Total	103,000		103,000
$103k Note II - November 2018 [Member]
Debt Instrument [Line Items]
Total	103,000		103,000
$153k Note - November 2018 [Member]
Debt Instrument [Line Items]
Total	153,000		153,000
$103k Note III - December 2018 [Member]
Debt Instrument [Line Items]
Total	103,000		103,000
$78k Note I - January 2019 [Member]
Debt Instrument [Line Items]
Total	78,000
$78k Note II - January 2019 [Member]
Debt Instrument [Line Items]
Total	$ 78,000
[1]	Denotes that convertible note payable is carried at fair value

Convertible Notes Payable (De_2

Convertible Notes Payable (Details 1) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Amortization of Debt Discount	$ 179,384	$ 140,262
Interest Expense	29,660	25,746
$550k Note - July 2016 [Member]
Amortization of Debt Discount
Interest Expense	8,137	8,137
$50k Note - July 2016 [Member]
Amortization of Debt Discount
Interest Expense	1,233	1,233
$111k Note - May 2017 [Member]
Amortization of Debt Discount		11,011
Interest Expense	4,078	4,078
$53k Note - July 2017 [Member]
Amortization of Debt Discount		1,520
Interest Expense		116
$35k Note - September 2017 [Member]
Amortization of Debt Discount		7,972
Interest Expense		614
$55k Note - September 2017 [Member]
Amortization of Debt Discount		10,849
Interest Expense		1,085
$53k Note II - October 2017 [Member]
Amortization of Debt Discount		17,036
Interest Expense		1,307
$171.5k Note - October 2017 [Member]
Amortization of Debt Discount		42,404
Interest Expense	1,785	4,229
$57.8k Note - January 2018 [Member]
Amortization of Debt Discount		13,923
Interest Expense		1,392
$112.8k Note - February 2018 [Member]
Amortization of Debt Discount		17,608
Interest Expense		1,761
$83k Note - February 2018 [Member]
Amortization of Debt Discount		10,460
Interest Expense		1,046
$105k Note - March 2018 [Member]
Amortization of Debt Discount		7,479
Interest Expense		748
$103k Note I - October 2018 [Member]
Amortization of Debt Discount	32,526
Interest Expense	2,540
$103k Note II - November 2018 [Member]
Amortization of Debt Discount	31,856
Interest Expense	2,540
$153k Note - November 2018 [Member]
Amortization of Debt Discount	50,440
Interest Expense	3,773
$103k Note III - December 2018 [Member]
Amortization of Debt Discount	25,397
Interest Expense	2,540
$78k Note I - January 2019 [Member]
Amortization of Debt Discount	21,714
Interest Expense	1,624
$78k Note II - January 2019 [Member]
Amortization of Debt Discount	17,451
Interest Expense	$ 1,410

Convertible Notes Payable (De_3

Convertible Notes Payable (Details 2) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Unamortized Discount	$ 363,089	$ 386,473
$103k Note I - October 2018 [Member]
Unamortized Discount	43,730	76,256
$103k Note II - November 2018 [Member]
Unamortized Discount	53,801	85,656
$153k Note - November 2018 [Member]
Unamortized Discount	79,022	129,462
$103k Note III - December 2018 [Member]
Unamortized Discount	69,701	95,099
$78k Note I - January 2019 [Member]
Unamortized Discount	56,286
$78k Note II - January 2019 [Member]
Unamortized Discount	$ 60,549

Convertible Notes Payable (De_4

Convertible Notes Payable (Details 3) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Change in Fair Value of Debt	$ 23,870	$ 63,312
Fair Value of Debt	802,404		$ 966,787
$550k Note - July 2016 [Member]
Change in Fair Value of Debt	16,838	46,298
Fair Value of Debt	611,651		594,813
$50k Note - July 2016 [Member]
Change in Fair Value of Debt	1,707	8,199
Fair Value of Debt	62,019		60,312
$111k Note - May 2017 [Member]
Change in Fair Value of Debt	3,544	8,815
Fair Value of Debt	128,734		125,190
$171.5k Note - October 2017 [Member]
Change in Fair Value of Debt	1,781
Fair Value of Debt			$ 186,472

Convertible Notes Payable (De_5

Convertible Notes Payable (Details 4) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Short-term Debt [Line Items]
Cash repayment		$ 209,682
Gain on extinguishment of debt	(139,798)	$ (325,223)
Convertible Notes Payable ($53,000) - July 2017 [Member]
Short-term Debt [Line Items]
Cash repayment	74,922
Less face value of convertible note payable retired	(53,000)
Less carrying value of derivative financial instruments arising from ECF	(53,893)
Less accrued interest	(2,644)
Plus carrying value of discount at extinguishment	18,427
Gain on extinguishment of debt	(16,188)
Convertible Notes Payable ($35,000) - September 2017 [Member]
Short-term Debt [Line Items]
Cash repayment	49,502
Less face value of convertible note payable retired	(35,000)
Less carrying value of derivative financial instruments arising from ECF	(37,269)
Less accrued interest	(1,716)
Plus carrying value of discount at extinguishment	12,705
Gain on extinguishment of debt	(11,778)
Convertible Notes Payable ($55,000) - September 2017 [Member]
Short-term Debt [Line Items]
Cash repayment	85,258
Less face value of convertible note payable retired	(55,000)
Less carrying value of derivative financial instruments arising from ECF	(69,687)
Less accrued interest	(2,759)
Plus carrying value of discount at extinguishment	27,425
Gain on extinguishment of debt	$ (14,763)

Convertible Notes Payable (De_6

Convertible Notes Payable (Details 5) - $78k Note I - January 2019 [Member] - USD ($)	Jan. 14, 2019	Jan. 24, 2018
Short-term Debt [Line Items]
Embedded conversion feature		$ 101,139
Original issue discount		3,000
Financing cost		(26,139)
Convertible note
Gross proceeds		$ 78,000
Embedded conversion feature	$ 78,088
Original issue discount	3,000
Fair value of shares recorded to equity	4,676
Financing cost	(7,764)
Convertible note
Gross proceeds	$ 78,000

Convertible Notes Payable (De_7

Convertible Notes Payable (Details Textual)

Jan. 14, 2019USD ($)

Aug. 07, 2018USD ($)$ / sharesshares

Mar. 05, 2018USD ($)

Feb. 02, 2018USD ($)

Jan. 02, 2018USD ($)

Jul. 07, 2016USD ($)$ / sharesshares

Aug. 16, 2018USD ($)$ / sharesshares

Mar. 28, 2018USD ($)$ / sharesshares

Feb. 13, 2018USD ($)

Oct. 27, 2017USD ($)

May 22, 2017USD ($)$ / sharesshares

Mar. 31, 2019USD ($)shares

Sep. 30, 2018USD ($)

Mar. 31, 2018USD ($)

Sep. 30, 2018USD ($)

Dec. 31, 2018USD ($)

Aug. 30, 2018$ / shares

Jan. 08, 2018USD ($)

Sep. 07, 2017USD ($)

Jul. 10, 2017USD ($)

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 1,420,404

$ 1,428,787

Net proceeds from issuance of convertible notes

150,000

$ 325,000

Amortization expense related to discounts

(179,384)

(154,835)

Original issue discount

$ 363,089

386,473

Expected dividend yield

0

Convertible note

$ 1,057,315

1,042,314

Interest expense

29,660

25,746

Unamortized discount

363,089

386,473

Change in fair value of debt

23,870

63,312

Loss on extinguishment of debt

(139,798)

(325,223)

Fair value of this instrument

802,404

966,787

Fair of warrants issued for professional service

14,743

$111k Note [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

128,734

[1]

125,190

Interest expense

4,078

4,078

Change in fair value of debt

3,544

8,815

Fair value of this instrument

128,734

125,190

$111k Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Percentage of fixed convertible secured promissory note

10.00%

Convertible secured promissory note face value

$ 111,000

Warrant to purchase of common stock exercise price | $ / shares

$ 0.75

Net proceeds from issuance of convertible notes

$ 100,000

Original issue discount

$ 11,000

Expected life

5 years

Note convertible into common shares | shares

317,143

Warrant to purchase of common stock, shares | shares

133,333

Note holder fixed price per share | $ / shares

$ 0.35

$111k Note [Member] | HLYK [Member]

Debt Instrument [Line Items]

Convertible secured promissory note maturity date

Jan. 22, 2018

Warrant to purchase of common stock exercise price | $ / shares

$ 0.05

Risk-free interest rate

2.59%

Expected life

5 years

Volatility

578.45%

Expected dividend yield

0

Warrant to purchase of common stock, shares | shares

125,000

Fair value of warrants calculated using Black-Scholes pricing model

$ 10,199

$50k Note [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

62,019

[1]

60,312

Interest expense

1,233

1,233

Change in fair value of debt

1,707

8,199

Fair value of this instrument

62,019

60,312

$50k Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Percentage of fixed convertible secured promissory note

10.00%

Convertible secured promissory note face value

$ 50,000

Convertible secured promissory note maturity date

Jul. 11, 2018

Common stock fixed price per share | $ / shares

$ 0.10

Net proceeds from issuance of convertible notes

$ 500,000

$550k Note [Member]

Debt Instrument [Line Items]

Interest expense

8,137

8,137

Change in fair value of debt

16,838

46,298

Fair value of this instrument

611,651

594,813

$550k Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Percentage of fixed convertible secured promissory note

6.00%

Convertible secured promissory note face value

$ 550,000

Convertible secured promissory note maturity date

Apr. 11, 2017

Common stock fixed price per share | $ / shares

$ 0.08

Net proceeds from issuance of convertible notes

$ 500,000

Original issue discount

$ 50,000

Note convertible into common shares | shares

6,875,000

$53k Note - July 2017 [Member]

Debt Instrument [Line Items]

Interest expense

116

$53k Note - July 2017 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 53,000

Accrued interest, for a one-time cash payment

$ 74,922

$78k Note – January 2019 [Member]

Debt Instrument [Line Items]

Net proceeds from issuance of convertible notes

$ 4,676

$78k Note – January 2019 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

78,000

Net proceeds from issuance of convertible notes

$ 3,000

Risk-free interest rate

2.57%

Expected life

9 months

Volatility

243.61%

Expected dividend yield

0

Convertible note conversion features, description

The $78k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 25% discount to the lowest bid or trading price of the Company’s common stock during the ten (10) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due.

Convertible note interest rate term

The $78k Note has an interest rate of 10% and a default interest rate of 24% and matures on October 14, 2019.

Fair value of warrants calculated using Black-Scholes pricing model

$ 78,088

Net charge on embedded conversion feature

$ 7,764

$105k Note - March 2018 [Member]

Debt Instrument [Line Items]

Interest expense

748

$105k Note - March 2018 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 105,000

Warrant to purchase of common stock exercise price | $ / shares

$ 0.35

Net proceeds from issuance of convertible notes

$ 5,000

Convertible note conversion features, description

The $113k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 9.9% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default, 110-150% of the outstanding principal and any interest due amount shall be immediately due, depending on the nature of the breach.

Convertible note interest rate term

The $105k Note has an interest rate of 10% and a default interest rate of 24% and matures on March 5, 2019.

Fair value of warrants calculated using Black-Scholes pricing model

$ 153,371

Loss on extinguishment of debt

$ 51,804

$113k Note [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 112,750

$113k Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Warrant to purchase of common stock exercise price | $ / shares

$ 0.25

Convertible note conversion features, description

The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the Note, 200% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due.

Convertible note interest rate term

The $113k Note has an interest rate of 10% and a default interest rate of 24% and matures on February 2, 2019.

Warrant to purchase of common stock, shares | shares

100,000

Fair value of warrants calculated using Black-Scholes pricing model

$ 50,614

$ 161,527

Loss on extinguishment of debt

$ 2,054

$83k Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 83,000

Warrant to purchase of common stock exercise price | $ / shares

$ 0.35

Convertible note conversion features, description

The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default, 200% of the outstanding principal and any interest due amount shall be immediately due.

Convertible note interest rate term

The $83k Note has an interest rate of 10% and a default interest rate of 24% and matures on February 13, 2019.

Warrant to purchase of common stock, shares | shares

237,143

Fair value of warrants calculated using Black-Scholes pricing model

$ 92,400

$ 119,512

Loss on extinguishment of debt

$ 51,251

$58k Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 57,750

Net proceeds from issuance of convertible notes

50,000

Original issue discount

$ 5,250

Convertible note conversion features, description

The $58k Note was convertible into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 28% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. On June 26, 2018, the holder agreed, without consideration, to reduce the discount to 28% of the volume weighted average price of the Company’s common stock for the 10 days prior to the conversion date. During third and fourth quarter of 2018, the holder of the $58k Note converted the entire principal balance of $57,750, as well as accrued interest in the amount of $3,786, into 384,839 shares of Company common stock. Accrued but unpaid interest of $21,990 was outstanding as of March 31, 2019.

Convertible note interest rate term

The $58k Note had an interest rate of 10% and a default interest rate of 18% and was scheduled to mature on January 2, 2019.

Net charge on embedded conversion feature

$ 32,652

$171.5k Note [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

186,472

Interest expense

1,785

4,229

Change in fair value of debt

1,781

Fair value of this instrument

$ 186,472

$171.5k Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 171,500

$ 171,500

Net proceeds from issuance of convertible notes

150,000

Original issue discount

$ 21,500

Note convertible into common shares | shares

2,512,821

Convertible note conversion features, description

The $171.5k Note was convertible into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 35% discount to the lowest closing bid price during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the $171.5k Note, 300% of the outstanding principal and any interest due amount was immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the $171.5k Note, 150% of the outstanding principal and any interest due amount was immediately due.

Convertible note interest rate term

The $171.5k Note had an interest rate of 10% and a default interest rate of 22% and matures on October 26, 2018.

$35k Note [Member]

Debt Instrument [Line Items]

Interest expense

$ 614

$35k Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 35,000

Accrued interest, for a one-time cash payment

$ 49,502

[1]

Denotes that convertible note payable is carried at fair value

Convertible Notes Payable (De_8

Convertible Notes Payable (Details Textual 1)

Jan. 14, 2019USD ($)

Aug. 07, 2018USD ($)$ / sharesshares

Jul. 18, 2018

Mar. 13, 2018USD ($)

Mar. 05, 2018USD ($)

Feb. 02, 2018USD ($)

Jan. 14, 2018USD ($)

Jan. 02, 2018USD ($)

Jul. 07, 2016USD ($)$ / sharesshares

Aug. 30, 2018USD ($)$ / shares

Aug. 16, 2018USD ($)$ / sharesshares

Mar. 28, 2018

Feb. 13, 2018USD ($)

Feb. 12, 2018USD ($)shares

Oct. 27, 2017USD ($)

May 22, 2017USD ($)$ / sharesshares

Mar. 31, 2019USD ($)shares

Sep. 30, 2018USD ($)

Mar. 31, 2018USD ($)

Sep. 30, 2018USD ($)

Dec. 31, 2018USD ($)

Sep. 11, 2017USD ($)

Sep. 07, 2017USD ($)

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 1,420,404

$ 1,428,787

Proceeds from issuance of convertible notes

150,000

$ 325,000

Original issue discount

$ 363,089

386,473

Expected dividend yield

0

Convertible note

$ 1,057,315

1,042,314

Financing cost

33,903

192,062

Interest expense

29,660

25,746

Repayment of notes payable and bank loans

(52,619)

Unamortized discount

363,089

386,473

Loss on extinguishment of debt

(139,798)

(325,223)

Fair of warrants issued for professional service

14,743

Convertible notes payable maturity date, description

Until December 31, 2019.

Michael Dent [Member]

Debt Instrument [Line Items]

Warrant to purchase of common stock, shares | shares

6,678,462

Fair of warrants issued for professional service

$ 337,466

Convertible notes payable maturity date, description

In connection with a $2,000,000 private placement by a third party investor, Dr. Dent agreed to extend the maturity date on all of the above notes until December 31, 2019.

The maturity dates of promissory notes with an aggregate face value of $177,500, which were originally scheduled to mature before September 30, 2018, by one year from the original maturity date.

$55k Note - September 2017 [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

611,651

[1]

594,813

Interest expense

1,085

$55k Note - September 2017 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 55,000

Interest accrued

$ 85,258

$171.5k Note - October 2017 [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

186,472

Interest expense

1,785

4,229

$171.5k Note - October 2017 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 171,500

$ 171,500

Proceeds from issuance of convertible notes

150,000

Original issue discount

$ 21,500

Note convertible into common shares | shares

2,512,821

Convertible note conversion features, description

The $171.5k Note was convertible into common stock of the Company by the holder at any time following 180 days after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 35% discount to the lowest closing bid price during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the $171.5k Note, 300% of the outstanding principal and any interest due amount was immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the $171.5k Note, 150% of the outstanding principal and any interest due amount was immediately due.

Convertible note interest rate term

The $171.5k Note had an interest rate of 10% and a default interest rate of 22% and matures on October 26, 2018.

Fifty Note [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 62,019

[1]

60,312

Interest expense

1,233

1,233

Fifty Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Percentage of fixed convertible secured promissory note

10.00%

Convertible secured promissory note face value

$ 50,000

Common stock fixed price per share | $ / shares

$ 0.10

Proceeds from issuance of convertible notes

$ 500,000

$55k Note - September 2017 [Member]

Debt Instrument [Line Items]

Interest expense

8,137

8,137

$55k Note - September 2017 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Percentage of fixed convertible secured promissory note

6.00%

Convertible secured promissory note face value

$ 550,000

Common stock fixed price per share | $ / shares

$ 0.08

Proceeds from issuance of convertible notes

$ 500,000

Original issue discount

$ 50,000

Note convertible into common shares | shares

6,875,000

$35k Note - September 2017 [Member]

Debt Instrument [Line Items]

Interest expense

614

$35k Note - September 2017 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 35,000

Interest accrued

$ 49,502

$111k Note [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

128,734

[1]

125,190

Interest expense

4,078

4,078

$111k Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Percentage of fixed convertible secured promissory note

10.00%

Convertible secured promissory note face value

$ 111,000

Warrant to purchase of common stock exercise price | $ / shares

$ 0.75

Proceeds from issuance of convertible notes

$ 100,000

Original issue discount

$ 11,000

Expected life

5 years

Note convertible into common shares | shares

317,143

Warrant to purchase of common stock, shares | shares

133,333

Note holder fixed price per share | $ / shares

$ 0.35

$58k Note - January 2018 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 57,750

Proceeds from issuance of convertible notes

50,000

Net proceeds

2,500

Original issue discount

$ 5,250

Convertible note conversion features, description

The $58k Note was convertible into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 28% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. On June 26, 2018, the holder agreed, without consideration, to reduce the discount to 28% of the volume weighted average price of the Company’s common stock for the 10 days prior to the conversion date. During third and fourth quarter of 2018, the holder of the $58k Note converted the entire principal balance of $57,750, as well as accrued interest in the amount of $3,786, into 384,839 shares of Company common stock. Accrued but unpaid interest of $21,990 was outstanding as of March 31, 2019.

Convertible note interest rate term

The $58k Note had an interest rate of 10% and a default interest rate of 18% and was scheduled to mature on January 2, 2019.

Net charge on embedded conversion feature

$ 32,652

$113k Note - February 2018 [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 112,750

Net proceeds

100,000

$113k Note - February 2018 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Warrant to purchase of common stock exercise price | $ / shares

$ 0.25

Net proceeds

$ 12,750

Convertible note conversion features, description

The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the Note, 200% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the Note, 150% of the outstanding principal and any interest due amount shall be immediately due.

Convertible note interest rate term

The $113k Note has an interest rate of 10% and a default interest rate of 24% and matures on February 2, 2019.

Warrant terms

3 years

Warrant to purchase of common stock, shares | shares

100,000

Fair value of warrants calculated using Black-Scholes pricing model

$ 50,614

$ 161,527

Loss on extinguishment of debt

$ 2,054

Interest accrued

$ 151,536

$83k Note - February 2018 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 83,000

Warrant to purchase of common stock exercise price | $ / shares

$ 0.35

Net proceeds

$ 75,000

Convertible note conversion features, description

The $113k Note may be converted into common stock of the Company by the holder at any time after the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default, 200% of the outstanding principal and any interest due amount shall be immediately due.

Convertible note interest rate term

The $83k Note has an interest rate of 10% and a default interest rate of 24% and matures on February 13, 2019.

Warrant terms

5 years

Warrant to purchase of common stock, shares | shares

237,143

Fair value of warrants calculated using Black-Scholes pricing model

$ 92,400

$ 119,512

Loss on extinguishment of debt

$ 51,251

Interest accrued

$ 111,596

$105k Note - March 2018 [Member]

Debt Instrument [Line Items]

Interest expense

748

$105k Note - March 2018 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

105,000

Warrant to purchase of common stock exercise price | $ / shares

$ 0.35

Proceeds from issuance of convertible notes

5,000

Net proceeds

$ 100,000

Convertible note conversion features, description

The $113k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 9.9% beneficial ownership limitation, at a conversion price per share equal to 40% discount to the lowest bid or trading price of the Company’s common stock during the twenty (20) trading days prior to the conversion date. Upon an event of default, 110-150% of the outstanding principal and any interest due amount shall be immediately due, depending on the nature of the breach.

Convertible note interest rate term

The $105k Note has an interest rate of 10% and a default interest rate of 24% and matures on March 5, 2019.

Fair value of warrants calculated using Black-Scholes pricing model

$ 153,371

Loss on extinguishment of debt

$ 51,804

Interest accrued

$ 140,697

$63k Note - April 2018 [Member]

Debt Instrument [Line Items]

Proceeds from issuance of convertible notes

$ 4,676

Net proceeds

75,000

$63k Note - April 2018 [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

78,000

Proceeds from issuance of convertible notes

3,000

Net proceeds

$ 75,000

Risk-free interest rate

2.57%

Expected life

9 months

Volatility

243.61%

Expected dividend yield

0

Financing cost

$ 78,088

Convertible note conversion features, description

The $78k Note may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 25% discount to the lowest bid or trading price of the Company’s common stock during the ten (10) trading days prior to the conversion date. Upon an event of default caused by the Company’s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company’s breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due.

Convertible note interest rate term

The $78k Note has an interest rate of 10% and a default interest rate of 24% and matures on October 14, 2019.

Fair value of warrants calculated using Black-Scholes pricing model

$ 78,088

Net charge on embedded conversion feature

7,764

$78k Note [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

78,000

Original issue discount

60,549

Interest expense

$ 1,410

Original issue discount

$ 3,000

$78k Note [Member] | Convertible Notes Payable [Member]

Debt Instrument [Line Items]

Convertible secured promissory note face value

$ 78,000

Proceeds from issuance of convertible notes

3,000

Net proceeds

$ 75,000

Risk-free interest rate

2.58%

Expected life

9 months 22 days

Volatility

243.03%

Expected dividend yield

0

Financing cost

$ 101,139

Convertible note conversion features, description

The $78k Note II may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the lowest bid or trading price of the Company's common stock during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company's failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due. Upon an event of default caused by the Company's breach of any other events of default specified in the note, 150% of the outstanding principal and any interest due amount shall be immediately due.

Convertible note interest rate term

The $78k Note II has an interest rate of 10% and a default interest rate of 22% and matures on November 15, 2019.

Fair value of warrants calculated using Black-Scholes pricing model

$ 101,139

[1]

Denotes that convertible note payable is carried at fair value

Derivative Financial Instrume_3

Derivative Financial Instruments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Debt Instrument [Line Items]
Balance of fair value	$ 800,440	$ 398,489
Inception of Derivative Financial Instruments	179,230	517,063
Change in Fair Value of Derivative Financial Instruments	(191,633)	14,621
Conversion of Derivative Financial Instruments	(207,182)	(160,850)
Balance of fair value	580,855	769,323
$171.5k Note - October 2017 [Member]
Debt Instrument [Line Items]
Balance of fair value	229,902	190,580
Inception of Derivative Financial Instruments
Change in Fair Value of Derivative Financial Instruments	(22,720)	11,979
Conversion of Derivative Financial Instruments	(207,182)
Balance of fair value		202,559
$103k Note I - October 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value	131,617
Inception of Derivative Financial Instruments
Change in Fair Value of Derivative Financial Instruments	(33,857)
Conversion of Derivative Financial Instruments
Balance of fair value	97,760
$103k Note II - November 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value	135,845
Inception of Derivative Financial Instruments
Change in Fair Value of Derivative Financial Instruments	(32,378)
Conversion of Derivative Financial Instruments
Balance of fair value	103,467
$153k Note - November 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value	157,426
Inception of Derivative Financial Instruments
Change in Fair Value of Derivative Financial Instruments	(45,408)
Conversion of Derivative Financial Instruments
Balance of fair value	112,018
$103k Note III - December 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value	145,650
Inception of Derivative Financial Instruments
Change in Fair Value of Derivative Financial Instruments	(28,544)
Conversion of Derivative Financial Instruments
Balance of fair value	117,106
$78k Note I - January 2019 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	78,088
Change in Fair Value of Derivative Financial Instruments	(14,573)
Conversion of Derivative Financial Instruments
Balance of fair value	63,515
$78k Note [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments	101,142
Change in Fair Value of Derivative Financial Instruments	(14,153)
Conversion of Derivative Financial Instruments
Balance of fair value	$ 86,989
$53k Note - July 2017 [Member]
Debt Instrument [Line Items]
Balance of fair value		48,876
Inception of Derivative Financial Instruments
Change in Fair Value of Derivative Financial Instruments		5,017
Conversion of Derivative Financial Instruments		(53,893)
Balance of fair value
$35k Note - September 2017 [Member]
Debt Instrument [Line Items]
Balance of fair value		36,161
Inception of Derivative Financial Instruments
Change in Fair Value of Derivative Financial Instruments		1,108
Conversion of Derivative Financial Instruments		(37,269)
Balance of fair value
$55k Note - September 2017 [Member]
Debt Instrument [Line Items]
Balance of fair value		64,656
Inception of Derivative Financial Instruments
Change in Fair Value of Derivative Financial Instruments		5,032
Conversion of Derivative Financial Instruments		(69,688)
Balance of fair value
$53k Note #2 - October 2017 [Member]
Debt Instrument [Line Items]
Balance of fair value		58,216
Inception of Derivative Financial Instruments
Change in Fair Value of Derivative Financial Instruments		617
Conversion of Derivative Financial Instruments
Balance of fair value		58,833
$57.8k Note - January 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments		82,653
Change in Fair Value of Derivative Financial Instruments		(2,905)
Conversion of Derivative Financial Instruments
Balance of fair value		79,748
$112.8k Note - February 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments		161,527
Change in Fair Value of Derivative Financial Instruments		(2,371)
Conversion of Derivative Financial Instruments
Balance of fair value		159,156
$83k Note - February 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments		119,512
Change in Fair Value of Derivative Financial Instruments		(1,525)
Conversion of Derivative Financial Instruments
Balance of fair value		117,987
$105k Note - March 2018 [Member]
Debt Instrument [Line Items]
Balance of fair value
Inception of Derivative Financial Instruments		153,371
Change in Fair Value of Derivative Financial Instruments		(2,331)
Conversion of Derivative Financial Instruments
Balance of fair value		$ 151,040

Derivative Financial Instrume_4

Derivative Financial Instruments (Details Textual)	3 Months Ended
	Mar. 31, 2019
Derivative Financial Instruments (Textual)
Expected dividend yield	0
Minimum [Member]
Derivative Financial Instruments (Textual)
Risk-free interest rate	2.40%
Expected life	3 months 29 days
Volatility	202.73%
Maximum [Member]
Derivative Financial Instruments (Textual)
Risk-free interest rate	2.73%
Expected life	1 year
Volatility	293.97%

Shareholders' Deficit (Details)

Shareholders' Deficit (Details) - Warrant [Member] - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of the period	46,161,463	20,526,387
Granted during the period	996,667	9,156,403
Exercised during the period	(2,099,256)
Terminated during the period
Outstanding at end of the period	45,058,874	29,682,790
Exercisable at end of the period	45,058,874	29,682,790
Weighted Average Exercise Price, Outstanding at beginning of the period	$ 0.18	$ 0.23
Weighted Average Exercise Price, Granted during the period	0.42	0.09
Weighted Average Exercise Price, Exercised during the period	0
Weighted Average Exercise Price, Terminated during the period
Weighted Average Exercise Price, Outstanding at end of the period	0.19	0.19
Weighted Average Exercise Price, Exercisable at end of the period	$ 0.19	$ 0.19
Weighted average remaining life	3 years 5 months	4 years 10 months 25 days

Shareholders' Deficit (Details

Shareholders' Deficit (Details 1) - Warrant [Member] - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	3 years 5 months	4 years 10 months 25 days
0.0001 to 0.09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding	18,157,768
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	3 years 7 months 6 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.06
Warrants/Options Exercisable, Number Exercisable	18,157,768
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.06
0.0001 to 0.09 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.09
0.0001 to 0.09 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.0001
0.10 to 0.24 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding	14,520,441
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	3 years 9 months 18 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.19
Warrants/Options Exercisable, Number Exercisable	14,520,441
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.19
0.10 to 0.24 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.24
0.10 to 0.24 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.10
0.25 to 0.49 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding	8,440,665
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	3 years 3 months 19 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.29
Warrants/Options Exercisable, Number Exercisable	8,440,665
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.29
0.25 to 0.49 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	0.49
0.25 to 0.49 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.25
0.50 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding	3,940,000
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	2 years 10 months 25 days
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.64
Warrants/Options Exercisable, Number Exercisable	3,940,000
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.64
0.50 to 1.00 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	1
0.50 to 1.00 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.50
0.05 to 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants/Options Outstanding, Number Outstanding	45,058,874
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	3 years 6 months
Warrants/Options Outstanding, Weighted-Average Exercise Price	$ 0.20
Warrants/Options Exercisable, Number Exercisable	45,058,874
Warrants/Options Exercisable, Weighted Average Exercise Price	$ 0.20
0.05 to 1.00 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	1
0.05 to 1.00 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Prices	$ 0.05

Shareholders' Deficit (Detail_2

Shareholders' Deficit (Details 2) - EIP [Member] - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of the period	1,738,750	1,498,750
Granted during the period	61,563
Terminated during the period
Outstanding at end of the period	1,800,313	1,498,750
Shares vested at period-end	1,336,563	1,058,750
Weighted average grant date fair value of shares granted during the period	$ 0.26
Aggregate grant date fair value of shares granted during the period	12,805
Shares available for grant pursuant to EIP at period-end	10,154,118	11,654,934

Shareholders' Deficit (Detail_3

Shareholders' Deficit (Details 3) - EIP [Member] - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested at beginning of period	540,000	628,750
Granted
Vested	(76,250)	(188,750)
Forfeited
Nonvested at end of period	463,750	440,000
Weighted Average Grant Date Fair Value, Nonvested at beginning of period	$ 0.16	$ 0.05
Weighted Average Grant Date Fair Value, Granted
Weighted Average Grant Date Fair Value, Vested	0.04	0.04
Weighted Average Grant Date Fair Value, Forfeited
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.18	$ 0.05

Shareholders' Deficit (Detail_4

Shareholders' Deficit (Details 4) - Employee Stock Option [Member] - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding at beginning of the period	3,707,996	2,349,996
Granted during the period	591,250
Exercised during the period	(154,166)
Forfeited during the period	(595,830)
Outstanding at end of the period	3,549,250	2,349,996
Weighted Average Exercise Price, Outstanding at beginning of the period	$ 0.18	$ 0.12
Weighted Average Exercise Price, Granted during the period	0.26
Weighted Average Exercise Price, Exercised during the period	0.20
Weighted Average Exercise Price, Forfeited during the period	0.20
Weighted Average Exercise Price, Outstanding at end of the period	$ 0.19	$ 0.12
Options exercisable at period-end	1,261,000	637,500
Weighted average remaining life (in years)	8 years 2 months 12 days	8 years 4 months 24 days
Weighted average grant date fair value of options granted during the period	$ 0.21
Options available for grant at period-end	10,154,118	11,654,934

Shareholders' Deficit (Detail_5

Shareholders' Deficit (Details 5) - Stock options [Member]	3 Months Ended
	Mar. 31, 2019$ / sharesshares
- to 0.10 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	$ 0.10
Options Outstanding, Number Outstanding | shares	1,733,000
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	6 years 10 months 25 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.08
Options Exercisable, Number Exercisable | shares	1,183,000
Options Exercisable, Weighted Average Exercise Price	$ 0.08
0.11 to 0.31 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number Outstanding | shares	1,816,250
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	9 years 6 months
Options Outstanding, Weighted-Average Exercise Price	$ 0.29
Options Exercisable, Number Exercisable | shares	78,000
Options Exercisable, Weighted Average Exercise Price	$ 0.31
0.11 to 0.31 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	0.31
0.11 to 0.31 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	$ 0.11
0.08 to 0.31 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Number Outstanding | shares	3,549,250
Warrants/Options Outstanding, Weighted - Average Remaining Contractual Life (years)	8 years 2 months 12 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.19
Options Exercisable, Number Exercisable | shares	1,261,000
Options Exercisable, Weighted Average Exercise Price	$ 0.10
0.08 to 0.31 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	0.31
0.08 to 0.31 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Prices	$ 0.08

Shareholders' Deficit (Detail_6

Shareholders' Deficit (Details 6) - Employee Stock Option [Member] - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested at beginning of period	2,332,413	1,774,996
Granted	591,250
Vested	(39,583)	(62,500)
Forfeited	(595,830)
Nonvested at end of period	2,288,250	1,712,496
Weighted Average Grant Date Fair Value, Nonvested at beginning of period	$ 0.13	$ 0.03
Weighted Average Grant Date Fair Value, Granted	0.21
Weighted Average Grant Date Fair Value, Vested	0.03	0.03
Weighted Average Grant Date Fair Value, Forfeited	0.02
Weighted Average Grant Date Fair Value, Nonvested at end of period	$ 0.18	$ 0.03

Shareholders' Deficit (Detail_7

Shareholders' Deficit (Details Textual) - USD ($)	Jan. 11, 2018	Feb. 28, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Sep. 03, 2014
Shareholders' Deficit (Textual)
Aggregate grant date fair value of warrants issued			$ 14,743
Fair value of warrant			54,257
General and administrative expense			$ 757,356	574,828
Authorized shares of common stock			500,000,000		500,000,000
Preferred shares						20,000,000
Employee Stock Option [Member]
Shareholders' Deficit (Textual)
Recognized expenses			$ 28,456	2,354
Unrecognized stock compensation			92,918
Stock based compensation recognized for grants			$ 32,779	$ 2,435
Minimum [Member]
Shareholders' Deficit (Textual)
Expected life (in years)			3 years
Expected volatility rate			212.96%	261.18%
Maximum [Member]
Shareholders' Deficit (Textual)
Expected life (in years)			5 years
Expected volatility rate			216.35%	278.45%
Warrant [Member]
Shareholders' Deficit (Textual)
Issued warrants			996,667	9,156,403
Risk-free interest rate, minimum			2.44%	2.23%
Risk-free interest rate, maximum			2.52%	2.65%
Expected life (in years)				5 years
Expected dividend yield			$ 0	$ 0
Aggregate grant date fair value of warrants issued			$ 294,707	582,311
Common Stock [Member]
Shareholders' Deficit (Textual)
Common shares, issued			205,301		114,080
Proceeds from sale of stock	$ 50,000	$ 200,000	$ 340,000
Sale of stock, shares	588,235	2,352,942	1,133,334
Sale of stock, per share	$ 0.085	$ 0.085	$ 0.30
Recognized expenses			$ 46,098	5,287
Warrants to purchase shares of common stock	588,235	1,764,706
Warrant to purchase of common stock exercise price	$ 0.15	$ 0.15
Warrant terms	5 years	5 years
Common Stock [Member] | Investment Agreement [Member]
Shareholders' Deficit (Textual)
Proceeds from sale of stock			$ 2,128,644	$ 42,969
Sale of stock, shares			493,226	1,563
Common Stock [Member] | Five-year warrants [Member]
Shareholders' Deficit (Textual)
Warrants to purchase shares of common stock			566,667
Warrant to purchase of common stock exercise price			$ 0.40
Warrant terms			5 years
Common Stock [Member] | Three-year warrants [Member]
Shareholders' Deficit (Textual)
Warrants to purchase shares of common stock			250,000
Warrant to purchase of common stock exercise price			$ 0.50
Warrant terms			3 years

Commitments and Contingencies_2

Commitments and Contingencies (Details)	Mar. 31, 2019USD ($)
2019 (April through December)	$ 219,859
2020	166,642
2021
2022
2023
Total lease payments	386,501
Less interest	(29,984)
Present value of lease liabilities	356,517
Operating Leases [Member]
2019 (April through December)	206,098
2020	162,055
2021
2022
2023
Total lease payments	368,153
Less interest	(28,957)
Present value of lease liabilities	339,196
Capital Leases [Member]
2019 (April through December)	13,761
2020	4,587
2021
2022
2023
Total lease payments	18,348
Less interest	(1,027)
Present value of lease liabilities	$ 17,321

Segment Reporting (Details)

Segment Reporting (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Revenue
Patient service revenue, net	$ 464,990	$ 645,639
Operating Expenses
Salaries and benefits	529,225	560,856
General and administrative	757,356	574,828
Depreciation and amortization	1,655	6,029
Total Operating Expenses	1,288,236	1,141,713
Loss from operations	(823,246)	(496,074)
Other Segment Information
Interest expense	46,322	40,347
Loss on extinguishment of debt	(139,798)	(325,223)
Financing cost	33,903	192,062
Amortization of original issue and debt discounts on convertible notes	179,384	154,835
Change in fair value of debt	29,697	57,946
Change in fair value of derivative financial instruments	(191,633)	14,621
Identifiable assets	1,086,286		$ 427,363
NWC [Member]
Revenue
Patient service revenue, net	464,990	645,639
Operating Expenses
Salaries and benefits	350,238	403,055
General and administrative	242,600	225,652
Depreciation and amortization	1,060	5,574
Total Operating Expenses	593,898	634,281
Loss from operations	(128,908)	11,358
Other Segment Information
Interest expense	5,828	5,697
Loss on extinguishment of debt
Financing cost
Amortization of original issue and debt discounts on convertible notes
Change in fair value of debt
Change in fair value of derivative financial instruments
Identifiable assets	520,535		184,912
HLYK [Member]
Revenue
Patient service revenue, net
Operating Expenses
Salaries and benefits	178,987	157,801
General and administrative	514,756	349,176
Depreciation and amortization	595	455
Total Operating Expenses	694,338	507,432
Loss from operations	(694,338)	(507,432)
Other Segment Information
Interest expense	40,494	34,650
Loss on extinguishment of debt	139,798	325,223
Financing cost	33,903	192,062
Amortization of original issue and debt discounts on convertible notes	179,384	154,835
Change in fair value of debt	29,697	57,946
Change in fair value of derivative financial instruments	(191,633)	$ 14,621
Identifiable assets	$ 565,751		$ 242,451

Segment Reporting (Details Text

Segment Reporting (Details Textual)	3 Months Ended
	Mar. 31, 2019USD ($)Segments	Mar. 31, 2018USD ($)
Segment Reporting (Textual)
Number of reportable segments | Segments	2
HLYK [Member]
Segment Reporting (Textual)
Subscription revenue billed and paid | $	$ 1,941	$ 6,888

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Total	$ 1,593,088
Fair value on a recurring basis	161,936	$ (72,567)	$ 1,784,726
Convertible notes payable [Member]
Fair value on a recurring basis	802,404		780,315
Notes payable to related party [Member]
Fair value on a recurring basis	209,829		203,971
Derivative financial instruments [Member]
Fair value on a recurring basis	580,855		800,440
Level 1 [Member]
Total
Level 1 [Member] | Convertible notes payable [Member]
Total
Level 1 [Member] | Notes payable to related party [Member]
Total
Level 1 [Member] | Derivative financial instruments [Member]
Total
Level 2 [Member]
Total
Level 2 [Member] | Convertible notes payable [Member]
Total
Level 2 [Member] | Notes payable to related party [Member]
Total
Level 2 [Member] | Derivative financial instruments [Member]
Total
Level 3 [Member]
Total	1,593,088		1,784,726
Level 3 [Member] | Convertible notes payable [Member]
Total	802,404		780,315
Fair value on a recurring basis	(23,869)	(54,497)
Level 3 [Member] | Notes payable to related party [Member]
Total	209,829		203,971
Fair value on a recurring basis	(5,828)	(3,449)
Level 3 [Member] | Derivative financial instruments [Member]
Total	580,855		$ 800,440
Fair value on a recurring basis	$ 191,633	$ (14,621)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	May 01, 2019	Apr. 12, 2019	Apr. 11, 2019	Apr. 03, 2019	Apr. 15, 2019	Apr. 04, 2019	Mar. 31, 2019	Dec. 31, 2018	Nov. 12, 2018
Subsequent Events (Textual)
Face value							$ 1,420,404	$ 1,428,787
Securities Purchase Agreement [Member]
Subsequent Events (Textual)
Face value									$ 103,000
One-time cash payment									$ 134,888
Subsequent Event [Member]
Subsequent Events (Textual)
Description of securities purchase agreement	The Company entered into a securities purchase agreement for the sale of a $103,000 convertible note. The note included $3,000 fees for net proceeds of $100,000. The note has an interest rate of 10% and a default interest rate of 22%, matures on February 28, 2020 and may be converted into common stock of the Company by the holder at any time after the 6-month anniversary of the issuance date, subject to a 4.99% beneficial ownership limitation, at a conversion price per share equal to a 39% discount to the lowest bid or trading price of the Company?s common stock during the fifteen (15) trading days prior to the conversion date. Upon an event of default caused by the Company?s failure to deliver shares upon a conversion pursuant to the terms of the note, 300% of the outstanding principal and any interest due amount shall be immediately due.
Subsequent Event [Member] | HCFM [Member]
Subsequent Events (Textual)
Acquired percentage		100.00%
Paid HCFM shareholders in cash		$ 500,000
Shares issued common stock		3,968,254
Earn out provision amount		$ 500,000
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Subsequent Events (Textual)
Sale of convertible note				$ 103,000
Fee for net proceeds			$ 9,000	3,000	$ 32,500
Net proceeds			$ 200,000	$ 100,000	$ 325,000
Interest rate			10.00%	10.00%	10.00%
Default interest rate			22.00%	22.00%
Mature date			Apr. 11, 2020	Feb. 28, 2020	Dec. 31, 2019
Beneficial ownership, percentage			4.99%	4.99%	9.99%
Conversion price per share, percentage			25.00%	39.00%
Outstanding principal and any interest, percentage			300.00%	300.00%	140.00%
Outstanding principal and any interest in default, percentage			150.00%	150.00%	40.00%
Face value			$ 209,000		$ 357,500	$ 103,000
One-time cash payment						$ 134,500
Conversion price					$ 0.20